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Individuals who are overweight or obese are at increased risk for cancer.  
However, the mechanistic link between obesity and cancer is poorly defined.  Adipose 
tissue produces hormones and pro-inflammatory cytokines with mitogenic properties.  
Many of these hormones and cytokines are altered in obese individuals and may lead to 
disruption of the normal balance between cell proliferation, differentiation, and apoptosis. 
Thus, the objective of this study was to determine how adipocyte-derived factors regulate 
the expression of genes that contribute to cell proliferation and migration.  To compare 
immediate early gene (cell proliferation) and epithelial-mesenchymal transition (cell 
migration) gene expression between untreated and treated cells, HeLa cells were exposed 
to IGF-1 (100ng/ml), leptin (100ng/ml), TNFα (10ng/ml), or IL-6 (10ng/ml) and QPCR 
analyses were carried out.  Immediate early gene expression was regulated by all four 
hormones.  Specifically, IGF-1 increased Jun, Fos, and Il-8; leptin increased Jun and Il-6; 
IL-6 increased Fos, Il-6, and Il-8; and TNFα increased Jun, Fos, Il-6, and Il-8 mRNA 
abundance.  Genes that regulate the epithelial-mesenchymal transition were also 
regulated by IGF-1, IL-6, and TNF.  Specifically, IGF-1 increased Snail1 and Snail2; IL-
6 increased Snail1; and TNF increased Jag1 mRNAs. Interestingly, the expression of 
Snail1, Snail2, JUN, and FOS was increased in the uterus of age-matched obese 
compared to normal-weight mice.  Western blot analyses demonstrated that these changes 
in mRNA abundance were associated with increased phosphorylation of Akt, Erk1/2, Jnk, 
and Stat3 in treated compared to untreated cells suggesting that these signaling factors 
play a role in the regulation of immediate early and epithelial-mesenchymal transition 
gene expression.  These studies demonstrate for the first time a mechanistic link between 
factors produced and secreted by adipocytes and the expression of genes associated with 
cell transformation, proliferation, and migration.  These cell functions play an important 
role in tumorigenesis and therefore changes in their expression may provide a plausible 
mechanism for obesity-dependent increases in a myriad of cancers.  
 
 
 
i 
TABLE OF CONTENTS 
Page 
 
 
LIST OF FIGURES. . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .iii 
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . iv 
 
CHAPTER 1: Literature Review .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 
           Clinical correlations between BMI and Cancer Risks  . . . . . . . . . . . . . . . . . . . . . . 1  
 Hormone Profiles and Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 
            IGF-1 system . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . 2 
Leptin . . . . . . . .. . . .. . . .. . . . .. . . . . . ..  . . . . . . . . . . . . . . . . . . . . . . . . . . 6    
IL-6 and TNF  . . .  . . . . . . . . .. . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .8      
Signaling Pathways Regulated by Adipocytokines . . . . . . . . . . . . . . . . . . . . . . . 10 
IGF-1 dependent signaling . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . .11 
Leptin and IL-6 dependent signaling. . .  . . . . . . . . . . . . . . . . . . . . . . . . . 11 
 TNF  dependent signaling . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 
Transcription Factors Activated by Adipocytokine Signaling . . . . . . . . . . . . . . . 13 
AP-1 Transcription Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 
FOXO Transcription Factors .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 
NF- B Transcription Factors .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 
STAT Transcription Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 
Epithelial Mesenchymal Transition. . . . . . . . . . . . . . . .  . . . . . . . . . .. . . . . . . . . .17 
 Snail . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . .17 
E-cadherin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 
ZEB1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19 
Literature Cited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . .. . . . . . . . . .28 
 
CHAPTER 2: Regulation of Immediate Early Genes and EMT Markers by IGF-1 in 
HeLa Cells and the Lethal Yellow Uterus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 
 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 36 
 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 
 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 
Hela cell culture and whole cell protein extracts . . . . . . . . . . . . . . . . . . . .39 
  Hela cell culture and RNA extraction. . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 
Reverse Transcription . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 
  Quantitative, Real-Time PCR (qPCR). . . . . . . . . . . . . . . . . . . . . . . . . . .  41 
  Western Blot Analyses . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .42 
Animals. . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . .. . . .43 
  Statistical Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . 44 
 Significant gene expression differences In Hela cells . . . . . . . . .  . . . . . .44 
Significant gene expression differences between LY and age matched B6  
            controls . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 
                         Signaling Pathways regulated by IGF-1 in Hela cells. . . .  . . . . . .. . . . . 45 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45 
 
 
ii 
  Literature Cited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58 
 
CHAPTER 3: Regulation of Immediate Early Genes and EMT Markers by Leptin   
in HeLa Cells. . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60 
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 60 
 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61 
 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 
Hela cell culture and whole cell protein extracts . . . . . . . . . . . . . . . . . . . .63 
  Hela cell culture and RNA extraction. . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 
Reverse Transcription . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . 64 
  Quantitative, Real-Time PCR (qPCR). . . . . . . . . . . . . . . . . . . . . . . . . . .  64 
  Western Blot Analyses . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .65 
  Statistical Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . 67 
 Significant gene expression differences in HeLa cells by leptin. . . . . . . . 67 
     Signaling Pathways regulated by Leptin in Hela cells cells . . . . . . .  …. .68 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 
  Literature Cited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .78 
 
CHAPTER 4: Regulation of Immediate Early and EMT Markers Genes by 
Pro-inflammatory Cytokines in HeLa Cells. . . . . . . . . . .. . . . . . . . . . . . . . . . . . . 82 
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 82 
 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83 
 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 
Hela cell culture and whole cell protein extracts . . . . . . . . . . . . . . . . . . . .85 
  Hela cell culture and RNA extraction. . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 
Reverse Transcription . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . .  . . . . . . . .86 
  Quantitative, Real-Time PCR (qPCR). . . . . . . . . . . . . . . . . . . . . . . . . . .  87 
  Western Blot Analyses . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .88 
  Statistical Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .89 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . .  .90 
 Significant gene expression differences in HeLa cells by IL-6 . .  . . . . . .90 
Signaling Pathways regulated by IL-6 in HeLa cells. . . . ……………. ...90 
Significant gene expression differences by in HeLa cells TNF . . . . . . . .91 
Signaling Pathways regulated by TNF in HeLa cells … . . . . . . . . . . . . 91 
 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .92 
  Literature Cited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 
 
CHAPTER 5: Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .110 
 
 
 
 
 
 
 
 
 
iii 
LIST OF FIGURES 
Page 
 
Figure 1.1. IGF-1 and IGF-2 interact with the IGF-1 receptor, the IGF-2 receptor and 
insulin receptor . . .. . . . .. . . . . . . . . . . . . .. . . . . . . . . . . . . . . . .  .  . . . . . .21 
 
Figure 1.2.  Free IGF-1 levels in lean and obese men and women . . . . . . . . . . . . . . . 22 
 
Figure 1.3.  Circulating levels of leptin, insulin, and IGF-1 in 3, 6, 12, and 24 week old 
female B6 and LY mice. . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . .23 
 
Figure 1.4.  TNF signal transduction pathway . . . . . . . . . .. . . . .. . . . . . . . . . . . . . . . .24 
 
Figure 1.5.  IGF-1, leptin, Il-6 and TNF  signal transduction pathways . . . . . . . . . . .25 
 
Figure 1.6.  IL-6 activates the JAK/STAT pathway and the MAPK cascade . . . . . . . 26 
 
Figure 1.7.  AP-1 functions in multistep tumorigenesis . . . . . . . . . . .. . . . . . . . . . . . . 27 
 
Figure 2.1. IGF-1 dependent regulation of IE and EMT genes expression in mouse 
uterus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52 
 
Figure 2.2.  IGF-1 dependent regulation of immediate early genes expression of HeLa 
cells. . . . . . . . . . . . . . . . . . . . .. . .. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .53 
 
Figure 2.3.  IGF-1 dependent regulation of epithelial transition markers genes 
expression of HeLa cells. . . . . . . . . . . . . . . . . . . . .. . .. . . . .. . . . . . . . . . .54 
 
 
Figure 2.4. IGF-1 activation of Akt phosphorylation and Erk1/2 phosphorylation. . .55 
 
Figure 2.5. IGF-1 activation of SAPK/JNK phosphorylation and STAT3 
phosphorylation. . . . . . . . . . . . .  . .. . . . . . . . . . . . .. . . . .. . . . .. . . . . . . . .56 
 
Figure 2.6. Lethal yellow mouse model. . . . . .  . .. . . . . . . . . . . . .. . . . .. . . . .. . . . .. .57 
 
 
Figure 3.1. Leptin dependent regulation of immediate early genes expression of HeLa 
cells. . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .. . . . . .. . .. . . . .. . . .. . . . ..  74 
 
Figure 3.2.  Leptin dependent regulation of epithelial transition markers genes 
expression of HeLa cells. . . . . . . . . . . . . . . . . . . . .. . . . .. . . . .. . . . . . . . .75 
 
Figure 3.3. Leptin activation of Erk1/2 phosphorylation. . . . . . . . . . . . . . . . . . . . . . .76 
 
 
 
iv 
Figure 3.4. Leptin activation of SAPK/JNK phosphorylation and STAT3 
phosphorylation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..77 
 
Figure 4.1. Il-6 dependent regulation of immediate early genes expression of HeLa 
cells. . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .. . . . . .. . .. . . . .. . . . . . . . . .99 
 
Figure 4.2.  Il-6 dependent regulation of epithelial transition markers genes expression 
of HeLa cells. . . . . . . . . . . . . . . . . . . . .. . . . .. . . . .. . . . . . . . . . . . . . . . . . 
100 
 
Figure 4.3. Il-6 activation of Erk1/2 phosphorylation. . . . . . . . . . . . . . . . . . . . . . . . 101 
 
Figure 4.4. Il-6  activation of SAPK/JNK phosphorylation and STAT3 
phosphorylation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 
 
Figure 4.5 TNFa dependent regulation of immediate early genes expression of HeLa 
cells. . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .. . . . . .. . .. . . . .. . . .. . . . . 103 
 
Figure 4.6  TNFa dependent regulation of epithelial transition markers genes 
expression of HeLa cells. . . . . . . . . . . . . . . . . . . . .. . . . .. . . . .. . . . . . . .104 
 
Figure 4.7. TNFa activation of Erk1/2 phosphorylation. . . . . . . . . . . . . . . . . . . . . . 105 
 
Figure 4.8. TNFa activation of SAPK/JNK phosphorylation and STAT3 
phosphorylation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..106 
 
Figure 5.1.  Experimental working model. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 
 
 
LIST OF TABLES 
Page 
 
Table 1.1. Markers of EMT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 
 
Table 2.1 Human Primer sequences used for QPCR analysis . . . . . . . . . . . . . . . . . 51 
 
Table 2.2 Mouse  Primer sequences used for QPCR analysis . . . . . . . . . . . . . . . . . 51 
 
Table 3.1 Human Primer sequences used for QPCR analysis. . . . . . . . . . . . . . . . . .73 
 
Table 4.1 Human Primer sequences used for QPCR analysis. . . . . . . . . . . . . . . . . .98 
1 
 
CHAPTER 1 
LITERATURE REVIEW 
Clinical correlations between BMI and Cancer Risks  
Obesity is a worldwide epidemic and health threat which arose as an unintended 
consequence of economic, social, and technological advances.  Obesity is defined based 
on the body mass index (BMI) measurement which is calculated by the following 
formula: BMI = weight (kg)/height squared (m
2
). BMI provides an accurate measurement 
to determine whether a patient is obese or overweight (1, 2) . A person is defined as 
overweight if BMI is greater than 25.0 but less than 29.9 and as obese if BMI is greater 
than 30.0.  Since 1980, over one billion adults have been classified as overweight or 
obese (3, 4).  Likewise, the CDC indicated that in 2007-2008 (5), approximately 72.5 
million adults in the United States were obese (CDC, unpublished data, 2010).  
Unfortunately, obesity is growing at an exponential rate in both developed and 
developing countries, and is even expanding among youth. In the United States, the ratio 
of people classified as obese is more than one-third of all adults.  
Patients who are obese experience several health problems which impact the 
quality of life.  Specifically, obese adults are at increased risk for development of 
coronary heart disease, hypertension, stroke, and type 2 diabetes.  In addition, overweight 
and obesity is associated with certain types of cancer including  kidney, breast 
(postmenopausal), endometrium, colon, gallbladder, ovary, pancreas and esophagus (6), 
(7). For example, after menopause, the risk for breast cancer is 1.5 times greater in an 
obese compared to an age-matched, normal-weight woman (8, 9). Likewise, Bergstrom et 
al. reported that obese women have up to a four-fold increased risk for endometrial 
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cancer than normal-weight women (10). In fact, approximately 40 percent of endometrial 
cancer patients are overweight or obese. Increased cancer risk due to obesity also impacts 
men.  For example, there is a weak positive relationship between male BMI and the risk 
for colon cancer (11). 
Despite the plethora of data linking obesity to increased cancer incidence, the 
mechanism of obesity-induced cancer development and progression is still unclear. 
Furthermore, it is likely that the specific mechanisms differ depending on cancer type.  
Adipose tissue is an endocrine organ and therefore, one possible mechanism includes 
chronic exposure to altered hormone and adipocytokine profiles associated with obesity 
(12, 13). Excess adipose tissue is characterized by altered endocrine hormone synthesis 
and increased macrophage infiltration which is an important source of pro-inflammatory 
cytokines produced by this tissue. Specifically, adipose tissue produces interleukin 6 (IL-
6), tumor necrosis factor alpha (TNF ), adiponectin, inhibitor of NF- B kinase b (IKKb), 
macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth 
factor (VEGF), plasminogen activator inhibitor 1 and haptoglobin, which act at both the 
local (autocrine/paracrine) and systemic (endocrine) level (14-16). Furthermore, chronic, 
excess adipose tissue alters the synthesis of endocrine hormones including sex steroids, 
insulin, and insulin-like growth factor (IGF).   
Hormone Profiles and Obesity 
  IGF System: Insulin-like growth factors (IGFs) are polypeptide hormones which 
are mainly produced by liver but are also synthesized by various other tissues including 
the ovary and uterus.  The IGF family consists of two ligands, IGF-1 and IGF-2, which 
both share approximately 50% structural homology to insulin (17). The synthesis of IGF-
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1 in the liver is stimulated by growth hormone (GH) and represents a primary mediator of 
GH action (18).  Conversely, the synthesis of IGF-2 is GH-independent.  Both IGF-1 and 
IGF-2 play an important role in the regulation of cell growth and survival via regulation 
of mitogenesis, differentiation, and apoptosis (19, 20). Thus, IGF-1 and IGF-2 have 
growth-promoting effects on almost every cell in the body, especially skeletal muscle, 
cartilage, bone, liver, kidney, nerves, skin, hematopoietic cell, and lungs, although the 
actions of IGF-2 are likely restricted to fetal development in mammals (19, 20). 
 The actions of the IGF ligands are mediated by one of three receptors, the IGF-1 
receptor, the IGF-2 receptor and the insulin receptor. The IGF-1 receptor (IGF1R) is a 
tyrosine kinase receptor which includes two α and two β subunits that have 60%, 
sequence homology to the insulin receptor (Fig. 1.1) (19). Both IGF-1 and IGF-2 bind 
with high affinity to the IGF1R which is expressed in all tissues except the liver. 
Activation of the IGF1R promotes cell survival, cell proliferation, protein synthesis, and 
DNA and RNA synthesis (19, 20). The IGF-2 receptor (IGF2R) is monomeric and 
structurally identical to the mannose 6 phosphate receptor (Fig. 1.1).  IGF-2 binds to the 
IGF2R with much higher affinity than IGF-1. Furthermore, the IGF2R does not have 
tyrosine kinase activity and acts as a decoy receptor which promotes degradation and 
therefore clearance of IGF2 from the circulation (19). In addition to these two IGF 
receptors, IGF-1 and IGF-2 are able to bind to the insulin receptor, although at a much 
lower affinity (i.e. 100-fold less than insulin).  However, studies have demonstrated that 
high concentrations of IGF-1 can induce insulin receptor dependent signaling (17, 21).  
The ability of IGFs to bind to these receptors is also dependent of the expression of 
binding proteins.  There are 6 binding proteins (IGFBP1 – IGFBP6) which interact with 
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both IGF-1 and IGF-2 and inhibit interaction of ligands with receptors as well as prolong 
ligand half-life (19). Interestingly, IGFBP-1, IGFBP-3, and IGFBP-5 can also potentiate 
IGF activity.  
The effect of an obese phenotype on the GH-IGF axis remains unclear with 
conflicting results documented in the literature. The concentration of serum total IGF 
shows little or nodiurnal variation by Baxter (22).  However, Frystyk et al. showed that 
obesity is associated with a decrease in GH. The level of GH secretion is diminished in 
obesity and reversible with weight loss.  However, obesity-dependent decreased GH level 
is not always correlated with decreased IGF-1 level in obesity (23, 24). In obesity, free 
IGF-1 levels are actually increased in obese men and to a lesser extent in woman (Fig. 1.2) 
(25).  In addition, individuals with low IGF-1 level tend to more easily weight gain and 
obesity (23, 24, 26).   Using a mouse model of obesity (Lethal Yellow; LY), our lab has 
demonstrated changes in total circulating IGF-1 levels during the development of obesity 
(Fig. 1.3) (Mack and Wood, unpublished data).  Specifically, at 6 weeks of age, prior to 
the onset of obesity, circulating levels of IGF-1 were significantly increased (P < 0.01) in 
LY female mice compared to age-matched female C57BL/6 (B6) control.  These 
increased levels decreased in LY mice returning to comparable levels to B6 mice by 12 
weeks of age (Mack and Wood, unpublished data).  Studies have also shown an 
association between circulating IGF-1 levels and bady fat in domestic livestock.  For 
example, the development of lower perirenal fat observed in low body weight involves an 
alteration of the IGF system as shown in the liver and skeletal muscle of growth-retarded 
fetuses and neonates in pig (27, 28). Furthermore, these changes in IGF-1 concentrations 
have an effect on reproductive performance in beef cattle (29).   
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The relationship between IGF1 and neoplasia has drawn attention for several 
years.  In 1987, Tricoli reported that increased IGF-1 mRNA is increased 3 to 5 fold in 
human colon cancer compared to the control (30). When IGF-1 was added to serum free 
media with the concentration of 10µg/L, the growth of mouse colon adenocarcinoma 
increased (31). Moreover, a high IGF-1/IGFBP-3 ratio would increase the risk of colon 
cancer development suggesting that IGF-1 stimulates the growth of colon cancer cells 
(32). In addition, IGF-1 has mitogenic effect on the St16, St42 and  MKN45 gastric 
cancer cell lines , as well as human pancreatic cell line such as ASPC-1and COLO357 
(33, 34). In lung cancer cells, there is increased IGF-1 concentration in the cancerous 
tissue, and IGF-1 stimulates the growth of the lung cancer cell line CALU-6 inducing a 
52% increase (35).  In breast cancer cells, IGF-I and IGF-II are potent mitogens, and 
combine with estrogen to stimulate cell growth in a synergistic manner (36). Ferlanetto 
reported that IGF-1 stimulated DNA synthesis in multiple breast cancer cell lines 
including MCF-7, T47D, MDA-MB-23 and HBL-100 (36). Clinical studies also 
demonstrated that there is elevated IGF-1 levels in breast cancer patients (37).  Finally, 
men with elevated IGF-1 concentrations are at increased risk for developing prostate 
cancer (37).   
Taken together, these data provide evidence that the IGF system is involved in 
cancer growth.  One mechanism of IGF-dependent tumorigenesis may be that IGFs are 
mitogenic and anti-apoptotic peptides that enhance the proliferation and reduce the death 
of various cell types. Angiogenesis also plays a critical role in the development of 
cancers. IGF-I is able to activate sphingosine kinase (SphK) in human endothelial cells, 
leading to sphingosine-1-phosphate (S1P) formation. Insulin-like growth factor binding 
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protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. There 
is also evidence that the increase of breast tumor angiogenesis depends on interactions of 
M6P/IGF-IIR with mannose 6-phosphate-containing proteins (38).   IGFs also play 
important roles in cancer metastasis.  Recent studies showed that numerous predictive 
markers of colorectal carcinoma metastasis include IGF-II, TGF-a, EGFR, matrix 
metalloproteinase (MMP)-2, vascular endothelial growth factor (VEGF) (17).  In 
melanoma patients, there is a significant correlation between high IGF-IR level and the 
risk of liver metastasis. Furthermore, overexpression of IGF-IR in the primary gastric 
tumor is correlated with increased lymph node metastasis (39-41).  Finally, high levels of 
IGF-1 and IGF-2 enhance choriocarcinoma cell adhesion and invasion (39-41). Taken 
together, these collective studies provides strong evidence that the IGF system is 
involved in human cancer progression and emphasizes the importance of targeting IGF 
signaling and developing drugs capable of inhibiting IGF signaling as anticancer therapy 
(42, 43). 
Leptin: Leptin is a peptide hormone of 16kDa and 167 amino acids.  It is one of 
the most important adipose derived hormones, which plays a key role in regulating 
energy intake and energy expenditure, and regulating appetite and metabolism. Leptin is 
the product of the "obesity" (ob) gene which was discovered in 1994 by Zhang and is 
located on chromosome 7 in humans (44). Leptin is expressed primarily in the adipocytes 
of white adipose tissue and, at lower levels, in gastric epithelium and placenta (45, 46). 
Interestingly, like other endocrine hormones, leptin levels fluctuate in a diurnal and 
pulsatile fashion. Circulating leptin levels reach maximum after midnight, whereas they 
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are lowest around noon. There is also evidence that glucocorticoids up-regulate leptin 
levels in the human (47, 48) 
Leptin interacts with six types of receptors including Ob-Ra–Ob-Rf, or LepRa-
LepRf.  Leptin receptors have two isoforms, long and short, with the short form generally 
located in peripheral tissue including the liver, kidney, heart, skeletal muscles, and the 
pancreas, and the long form mainly expressed in the hypothalamus.  The main function of 
leptin in the hypothalamic neurons is to regulate appetite control.  Specifically, leptin 
reduces food intake by upregulating anorexigenic (appetite-reducing) neuropeptides, such 
as -melanocyte-stimulating hormone, and downregulating orexigenic factors, primarily 
neuropeptide Y (NPY) in the hypothalamus (47, 48).   
In obese individuals circulating leptin levels are generally higher than in normal-
weight individuals. These higher leptin concentrations in the serum of obese individuals 
is associated with both increased fat mass and increased leptin release from larger 
adipocytes (49).  Unlike IGF-1, there is a significant correlation between leptin levels and 
percent body fat in both sexes. However, the absolute peak leptin level is higher in 
women than in men (49, 50).  In ruminant animals, leptin level in serum fluctuates with 
body condition in a similar pattern as humans. Furthermore, leptin levels are associated 
with different nutritional conditions in cattle. For example, plasma leptin concentration 
measured 4 h after meal is positively related to feed intake and to plasma 3-OH-butyrate, 
and negatively related to plasma NEFA.  Leptin concentrations decrease after meal intake 
in well-fed cows but increase in underfed cows (51, 52).  In our mouse model of obesity, 
leptin is significantly increased (P < 0.001) in LY compared to B6 females at 12 and 24 
weeks of age (Fig 1.3; Mack and Wood, unpublished data).  Based on these data, leptin 
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was originally considered a good target for treating obesity by the scientific and clinical 
communities.  However, the complexity of the leptin axis and the development of leptin 
resistance make leptin a poor target for obesity therapy.   
Given that obesity is risk factor in various cancers and leptin plays a significant 
role in obesity, the relationship between leptin levels and cancer risk has been seriously 
considered. Several reports demonstrate a role for leptin in the pathogenesis of a series of 
different forms of cancers, including cancers of the male and female reproductive tract 
(breast, endometrial, ovarian and prostate cancer), cancers of the gastrointestinal tract 
(esophagus, gastric and colon cancer) and leukemias (49).  In breast cancer, leptin 
increases cell proliferation and cell transformation (anchorage-independent growth).  One 
mechanism for these cellular changes is leptin-dependent increases in AP-1 activation 
which results in increased cdk2, cyclinD1 and P450 aromatase expression and 
hyperphosphorylation of the retinoblastoma (Rb) protein. Furthermore, it induces c-myc 
expression and stabilizes ERα expression (53, 54).  In colorectal cancer, leptin increases 
cell growth through the ERK1/2 pathway, increases cell invasion via an PI-3K, Rho- and 
Rac-dependent pathways, and reduces cell apoptosis via stimulation of NF-kB signaling 
(55). In prostate cancer, leptin increases cell proliferation and suppresses apoptosis (56). 
In pancreatic cancer, leptin decreases cell proliferation through stimulation of STAT3 and 
STAT5b phosphorylation (57). In ovarian and lung cancer, leptin increases proliferation 
through the ERK1/2 pathway (58, 59). 
 IL-6 and TNF : Adipose tissue is not only the source of endocrine hormones, but 
is also infiltrated with macrophages which are an important source of inflammatory 
factors. In fact, excess adipose tissue associated with obesity is recognized as a chronic 
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inflammatory organ characterized by high expression of  interleukin 6 (IL-6) , tumor 
necrosis factor alpha (TNF , inhibitor of NF- B kinase b (IKKb), macrophage 
migration inhibitory factor, nerve growth factor, vascular endothelial growth factor, 
plasminogen activator inhibitor 1 and haptoglobin; increased acute-phase reactants, and 
activation of inflammatory signaling pathways (15, 16).  For example, adipose tissue is a 
significant source of circulating TNF   in most rodent models of obesity as well as 
human cases of obesity (60, 61). IL-6 is also produced by human adipose tissue and its 
circulating levels increase with the increased value of BMI (62, 63). 
Interleukin 6 and TNF  are multifunctional cytokines that are traditionally 
involved in the regulation of the immune response, hematopoiesis, and inflammation.  
Interleukin-6 is secreted by T cells and macrophages in response to trauma and mainly 
acts as a B cell differentiation factor. Interleukin-6 binds to the sIL-6 receptor (gp80, 
present either on the cell surface or in solution) resulting in dimerization of gp80 and the 
transmembrane gp130 and the activation of Janus kinase (JAK)(64).  Tumor necrosis 
factor a belongs to a superfamily of ligands which regulate the establishment of 
multicellular structures such as lymphoid organs, hair follicles, bone, and lactating 
mammary gland (65).  Upon stimulation, macrophages produce TNF  which is a 26-kDa 
transmembrane protein that is cleaved into a 17-kDa biologically active protein. 
Biologically active TNF  binds to one of two receptors, 55-kd (TNFR I) or 75-kd (TNFR 
II), which are found on most cells.  The interaction of biologically active TNF  with 
these receptors results in multiple cellular responses including apoptosis (most cells), cell 
proliferation (lymphocytes), bone resorption, and insulin resistance (Fig. 1.4) (66). 
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Cytokines are known to have both tumor-promoting and inhibitory effects with 
these opposing effects dependent on their relative concentrations and the presence of 
other factors (67).  Furthermore, inflammation is recognized to play important roles in the 
pathogenesis of many types of malignancies. Given the ability of adipose cells to produce 
cytokines especially during obesity, there could be an association between the pro-
inflammatory cytokine produced by adipose cells and the increased risk of cancer in 
obesity.  Indeed, elevated circulating IL-6 levels have been reported in breast cancer 
patients indicating that IL-6 levels may represent an early marker of breast tumors (67, 
68).  In addition, Grivennikov and Bollrath have demonstrated the contribution of 
interleukin-6 and its downstream effector STAT3 on colitis-associated colon cancer (69, 
70).  Conversely, TNF  generally inhibits tumorigenesis and viral replication. Recently, 
TNF  has been used as a regional treatment of locally advanced soft tissue sarcomas and 
metastatic melanomas and other tumors (71). Together with chemotherapeutic drugs, 
TNF  shows a synergistic antitumor effect (72). However, TNF-α alone induced only a 
mild central necrosis with no objective tumor response observed. In rat models, 
chemotherapeutic drugs with TNF-α improved the accumulation of selectively tumor up 
to 3 to 6 fold (71, 72). In addition, to these roles of IL-6 and TNF , other bioactive 
peptides  produced the adipose cell promote angiogenesis associated with metastasis 
including vascular endothelial growth factor, hepatocyte growth factor, and heparin-
binding epidermal growth factor-like growth factor (68). 
Signaling Pathways Regulated by Adiopocytokines 
The interaction of adipocytokine ligands with their receptors stimulates multiple 
signal transduction pathways.  Figure 1.5 shows the complex signaling network 
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(including cross-talk between pathways) that functions downstream of the insulin 
receptor (IR), the IGF-1 receptor, TNFα receptor, IL-6 receptor and leptin receptor (73). 
IGF-1 dependent signaling: When the IGF-1R heterotetramer is activated, the 
IRS-1 complex is recruited and phosphorylated, resulting in several signal transduction 
cascades to be activated including the phosphotidylinositol-3 kinase (PI3K)/Akt pathway 
(Fig. 1.5). Specifically, the lipid products of the PI3-kinase activates a cascade of PI (3, 4, 
5)-phosphate (PIP3)-dependent serine/threonine kinases including PDK1. Substrates of 
this kinase include PKC isoforms, the serum and glucocorticoid-inducible kinase SGK 
and the product of the Akt proto-oncogene. The activation of Akt is an important and 
central mediator of IGF-1action on glucose metabolism, cell proliferation and 
differentiation, and protein synthesis. In addition to Akt, IGF-1 activation of PI3K can 
stimulate c-jun N-terminal kinase (JNK/SAPK) resulting in increased activity of the AP-1 
transcription factors (74). For example, Poulaki et al demonstrated that systemic 
inhibition of IGF-I signaling with a receptor-neutralizing antibody, or with inhibitors of 
PI-3 kinase (PI-3K), c-Jun kinase (JNK), or Akt suppressed retinal Akt, JNK and AP-1 
activity. In addition, intravenous administration of IGF-I increased retinal Akt, JNK and 
AP-1 activity (74). One mechanism that low IGF-I decreases cancer is that reduced 
circulating IGF-I level attenuates activation of Akt and mTOR signaling pathways (73, 
75). 
 Leptin- and IL-6 dependent signaling: Leptin interaction with its 
receptors including Ob-Ra–Ob-Rf, or LepRa-LepRf  activates the Jak-Stat and mitogen 
activated protein kinase (MAPK) signal transduction pathways (73, 76)(77). Mostly, 
Leptin binding to the extracellular domain of the long form of the leptin receptor ( LRb) 
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which is crucial for leptin action and mainly expressed at basomedial hypothalamus, then 
activates the JAK2 tyrosine kinase which associates with LRb via the Box 1 motif and 
intracellular amino acids 31–36 of LRb (78). The long form of the receptor is crucial for 
leptin action and mainly expressed at basomedial hypothalamus (79). Short form may 
relate to leptin across the blood-brain barrier. The three primary intracellular signaling 
pathways emanate from LRb, including JAK2-Tyr 1138-stat3 pathway, Tyr 985 - SHP2 - 
ERK pathway and JAK2 tyrosine phosphorylation sites (78). Activation of JAK2 results 
in interaction with a conserved SH2 domain containing protein and phosphorylation and 
dimerization of STATs (Fig.1.5) (73). Suppressors of cytokine signaling (SOCS) are 
recently identified inhibitors of the Janus kinase (JAK)/signal transducers and activators 
of transcription (STAT) pathway (79). Increase in SOCS mRNA is observed when cells 
are exposed to a wide range of cytokines or growth factors , such as IL-4, IL-6, GH, 
Leptin (80). In fact, the phosphorylated STAT dimer translocates to the nucleus to 
activate target genes and SOCS transcription. SOCS-1 and SOCS-3 inhibit cytokine 
signaling in a feedback manner by inhibiting JAK or by inhibiting the activated receptor 
complex (79).  
IL-6 interaction with its receptor also activates the JAK/STAT signaling pathway.  
Specifically, IL-6 binds to -receptor subunits of IL-6R (gp 80) which are not involved in 
the intracellular signal-transduction cascade. After ligand binding, the cytokine and gp 80 
complex are able to efficiently dimerize with gp 130 which is the signal-transducing 
receptor component (81, 82), activate JAK and recruit STAT family members (Figure 
1.6)(64). Activation of JAK also results in the recruitment of SH2 domain protein, and 
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subsequently increased activity of the mitogen-activated protein kinase (MAPK) cascade. 
Thus, MAPK cascade is another important pathway stimulated by IL-6 (73, 83). 
TNFα dependent signaling:  TNFα exerts its biological action through activation 
of TNFRI and II which in turn activate the extracellular signal-regulated kinase (ERK-
1/2), p38 mitogen-activated protein kinase (p38 MAPK), phosphoinositide 3-kinase 
(PI3K)/Akt and nuclear factor-κB (NF-κB) pathways. TNFRI initiates the majority of 
TNF's function. The binding of TNF to TNF-R1 results in the activation of two major 
transcription factors, nuclear factor κB (NF-κB) and c-Jun. which is responsible for the 
inducible expression of genes important for diverse biological processes, including cell 
growth and death, development, oncogenesis, and immune, inflammatory, and stress 
responses (66). The chemical inhibitor LY294002 which blocks PI3K activity inhibits 
TNFα-induced Akt and ERK phosphorylation. Likewise, the IKK-2 inhibitor IMD-0354 
readily prevents TNFα-induced IκB-α phosphorylation and degradation, and thus 
activates NFkB activation. In addition, TNFα is able to induce IL-6 expression via 
TNFRI, which is dependent on p38 MAPK. Activation of IL-6 mRNA expression by 
TNF-α, can also be regulated by JNK via PI3K/Akt/NF-kappaB axis (73, 84). Tumor 
necrosis factor receptor-associated factors (TRAFS) are adaptor proteins that couple the 
tumor necrosis factor receptor family to signaling pathways.  TRAF2, TRAF5 and 
TRAF6 have been demonstrated to mediate activation of NF-kB and JNK, which is 
important pathway of TNFa (85). 
 
Transcription Factors activated by Adipocytokine Signaling 
AP-1 transcription factors: According to Liu's report, IGF-1 also activated the 
AP-1 (86). AP-1 converts extracellular signals into cell and make changes of expression 
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of specific target genes which harbour AP-1 binding site(s) in their promoter or enhancer 
regions. The family of AP-1 transcription factors includes Fos, Jun and ATF families of 
proteins (86-88). Normally, these AP-1 factors bind to the12-O-tetradecanoylphorbol-13-
acetate (TPA) response elements (5′-TGAG/CTCA-3′) or the cAMP response elements 
(CRE,5′-TGACGTCA-3′)(86). AP-1 activity is regulated by interactions with other 
transcriptional regulators and mediated by upstream kinases which link AP-1 to various 
signal pathways including MAPK and JNK (86). AP-1 transcription factors are involved 
in a large variety of biological processes such as cell differentiation, proliferation, 
apoptosis and oncogenic transformation.  For example, Jochum et al. show that c-Jun 
binds to the promoter of the P53 and cyclin D1, and then inhibit the p53 gene expression 
and stimulate the cycline D1 gene expression during mouse development and in a 
tumorigenesis model (Fig. 1.7).  C-Fos and FosB also binds to the promoter of the 
cyclinD1 and stimulate the gene expression of cyclinD1. JunD can bind to the promoter 
of Ras and inhibit the gene expression of Ras, while Jun B binds to the promoter of p16 
and stimulates the gene expression of p16 (86). AP-1 transcription factors play important 
role in cell differentiation, proliferation, apoptosis and oncogenic transformation. 
FOXO transcription factors: In addition to AP-1, several other transcription 
factor families are the target of signaling pathways activated by adipocytokines including 
FOXO family, NF B family, and Stat family.  FOXO (Forkhead box o) transcription 
factors play crucial roles in cell growth, proliferation, differentition, metabolism and 
stress tolerance. FOXO protein sequence contains 80 to 100 amino acids, which form a 
forkhead motif that looks like butterfly in loops and is also called the winged helix motif 
that binds to DNA.  They belong to helix-turn-helix class of proteins. Four members of 
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FOXO family have been discovered. They are FOXO1, FOXO3, FOXO4 and FOXO6 
(89, 90).  FOXO activity is modified post-translationally due to phosphorylation, 
acetylation and ubiquitination.  For example, Akt/PKB signaling inhibits FOXO activity 
through phosphorylation which causes them to be translocated out of the nucleus (91). 
FOXO1 is able to interact with TSC2, androgen receptor, estrogen receptor alpha, and 
CREB binding protein (92, 93). FOXO3 functions as a trigger for apoptosis through 
activation of Bim and PUMA, or down-regulation of anti-apoptotic proteins FLIP (94). 
FOXO3 is known as a tumour suppressor, and inhibition of FOXO3 tends to enhance 
tumorigenesis (95).  
NF- B transcription factors: NF-κB is a protein complex of transcription factors, 
with the name nuclear factor kappa-light-chain-enhancer of activated B cells. NF-κB 
family consists of 5 members: RelA, RelB, c-Rel NF-κB1 and NF-κB2, which all contain 
a Rel domain in their N-terminus.  The NF-κB1 and NF-κB2 proteins are derived from 
precursor proteins p105 and p100 respectively, through selective degradation of C-
terminal ankyrin repeat region by the ubiquitin/proteasome pathway. NF-κB is widely 
distributed in all animal cell types. Its functions are involved in cellular responses to 
stress, cytokines, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens 
(96). The kappa light chains of NF-κB are critical components of immunoglobulins 
allows NF-κB to be crucial in the regulation of the immune responses. Generally, 
inactivated NF-κB is located in the cytosol bound by the inhibitor IκBα. Once activated 
by certain stimuli (e.g. leptin) (97), IκB kinase (IKK) is activated and is able to 
phosphorylate the IκBα protein, leading to its ubiquitination, which results in the 
separation of IκBα from NF-κB, and further degradation of IκBα by the proteosome. As a 
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consequence, the activated NF-κB is translocated into the nucleus. Active NF-κB is able 
to bind to the promoters of target genes, and initiate gene transcription (98). IGF-1 is able 
to keep sustained activation of NF- B, but independent of IKK phosphorylation (99).  In 
addition, NF- B can be activated by TNF-  via phosphatidylcholine-specific 
phospholipase C-induced "acidic" sphingomyelin breakdown (100). TNF  is also able to 
activate NF-kB through MAPK and caspase pathways leading to apoptosis. Interestingly, 
both TNF   and IL-1 activate NF B using MAPK signaling pathway in a synergistic 
manner (101). 
STAT transcription factors: Signal transducer and activator of transcription 
proteins (STATs) are transcription factors, which play crucial roles in cell growth, 
survival and differentiation. There are seven members in STAT family: STAT1, STAT2, 
STAT3, STAT5a, STAT5b, and STAT6, which are activated by JAK.  Janus kinase 
phosphorylates specific tyrosine residues in the STAT protein.  When the phosphorylated 
dimers of STAT are activated, they are transported in the nucleus through importing a/b 
and RanGDP complex. In the nucleus, STAT dimers activate transcription of target genes 
by binding to their promoter regions of genes at gamma activated site (GAS) motif. The 
STAT proteins are inactivated once they are de-phosphorylated by nuclear phosphatases 
(102, 103). Dysregulation of the STAT pathway is involved in the formation of primary 
tumours and leads to increased angiogenesis, enhanced survival of tumours and 
immunosuppression (102, 103).    
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Epithelial Mesenchymal Transition  
Epithelial Mesenchymal Transition (EMT) is a normal developmental process 
characterized by inhibition of E-cadherin expression, loss of cell adhesion and increase of 
cell mobility. There are three types of EMTs (104, 105). Type 1 EMT is seen in primitive 
epithelial cells transitioning to motile mesenchymal cells during gastrulation and in 
primitive neuroepithelial cells which form migrating neural crest cells. Type 1 EMT is 
also associated with implantation. Type 2 EMT takes place during secondary epithelial or 
endothelial cells transition to resident tissue fibroblasts and is involved in wound healing, 
tissue regeneration, and organ fibrosis.  Thus, both Type 1 and Type 2 EMT are 
associated with normal biological functions during development and wound repair, 
respectively.  Conversely, type 3 EMT occurs in neoplastic cells and is involved in 
carcinoma cell invasion and metastasis. Carcinoma cells undergoing a type 3 EMT 
invade and metastasize and thereby the primary nodules transition to metastatic tumor 
cells and migrate by blood to form secondary distant nodules (106). Clarification of EMT 
process at the molecular level would help to understand mechanisms of cancer 
progression, detection of cancer metastases, and therapeutic intervention. There is a 
variety of biomarkers to use to detect all three subtypes of EMT (Table 1.1) (105), 
including cell-surface markers, cytoskeletal markers, extracellular matrix proteins, 
transcription factors and micro RNAs. 
Snail: The Snail family of zinc finger transcription factors, Snail1 and Snail2, are 
inducers of the EMT.  Snail genes are expressed in all EMT processes resulting in the 
conversion of cells from epithelial to mesenchymal with migratory properties. Thus, 
Snail-induced EMT is involved in formation of tissues and organs during embryonic 
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development and also the invasion and metastasis of carcinoma cells during 
tumorigenesis.  In addition, Snail genes also act as survival factors and inducers of cell 
movement independent of the induction of EMT.  Snail-induced EMT is mostly due to 
the repression of E-cadherin gene expression. Snail also regulates other aspects of the 
EMT such as suppressing cyclin D protein , cyclin-dependent kinase 4 and the expression 
of caspase, DNA fragmentation factor, Bcl-interaction death agonist, increasing MMP 
expression., and increasing expression of mesenchymal cell marker such as fibronectin 
and vitrionectin (105). Interestingly, pro-inflammatory cytokines and hormones released 
by adipose tissue are associated with Snail stabilization. In Snail expression knockdown 
inflammation-mediated breast cancer metastasis model, it shows the inhibition of 
inflammatory cytokines induced EMT. Snail can be stabilized by the inflammatory 
cytokine TNF  through activation of the NF-kappaB pathway (107).  
E-cadherin: Cadherin-1 (CDH1, E-cadherin), also known as CD324, is a tumor 
suppressor gene (108). In epithelial tissues, E-cadherin  is localized on the surfaces of 
epithelial cells at adherent junctions and plays an important  role in cell to cell adhesion 
(109).  Specifically, calcium-dependent interactions among E-cadherin molecules are 
important to mediate and maintain the adherent junctions of epithelial cell-cell contact 
(110).  In cancer cells, the function of E-cadherin is associated with the dedifferentiation/ 
aggressiveness of tumours and the transition from transformed cells to the invasive 
phenotype. In fact, E-cadherin acts as an invasion-suppressor gene. Loss of E-cadherin is 
considered to be diagnostic of a poor clinical prognosis with benign lesions to invasive, 
metastatic cancer. In addition, CDH1 knockout promotes cancer cell proliferation, 
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invasion and metastasis, including gastric, breast, colorectal, thyroid, and ovarian cancers 
(111).  
ZEB1: Zinc finger E-box binding homeobox 1 (ZEB1), binds to E-box-like 
elements that overlap with those bound by Snail family transcription factors.  ZEB1 is 
normally expressed in proliferating mesenchymal and neural progenitors. In fact, ZEB is 
EMT-inducer and transcriptional repressor which promotes invasion and metastasis (112). 
ZEB1 is a crucial promoter of metastasis and inhibits expression of the microRNA-200 
(miR-200) family. ZEB1 links EMT-activation by suppressing stemness-inhibiting 
microRNAs (miRNAs) and thereby acts as a promoter of mobile, migrating cancer stem 
cells (112)(111). In cancer, overexpression of ZEB1 is associated with repression of E-
cadherin. ZEB1 is expressed in most of poorly differentiated pancreatic cancers and in 
invasive, undifferentiated tumor cells of pancreatic adenocarcinomas.  Heterozygous 
mutation of ZEB1 also leads to craniofacial abnormalities such as cleft secondary palate 
and defective nasal formation. In a knockdown mouse model, decreased ZEB1 leads to 
an epithelial transition without increased expression of E-cadherin and reduces not only 
cancer cell invasion and metastasis, but also the number of tumor-bearing mice and the 
average size of primary tumors (111).  
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Table 1.1. Biomarkers for epithelial-mesenchymal transitions. Adapted from (105). 
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Figure 1.1.  IGF-1 and IGF-2 interact with the IGF-1 receptor (IGF-1 R), the IGF-2 
receptor (IGF-2 R) and insulin receptor (insulin R).  IGF1-R and insulin R are 
tyrosine kinase receptors that mediate overlapping functions of the IGF ligands.  The 
IGF-2 R is structurally identical to the mannose 6 phosphate (M6P) receptor and 
promotes degradation of the ligand.  Adapted from (19). 
22 
 
  
  
 
 
 
 
 
 
 
 
Figure 1.2.  Free IGF-1 levels in lean and obese men and women. There is an 
increased free IGF-1 level in obesity, However, less elevated free IGF-1 level in woman 
compare to man. The white bars are lean, grey bars are overweight, and black bars are 
obese The white bar is controls (BMI < 25),  while the gray bar show  moderate obesity 
(25 < BMI< 30), and black bar shows  severe obesity(BMI>30). Adapted from (25).   
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Figure 1.3. Circulating levels of leptin (ng/ml), insulin (ng/ml), and IGF-1 (ng/ml) in 
3, 6, 12, and 24 week old female B6 and LY mice. Circulating levels of leptin (ng/ml), 
insulin (ng/ml), and IGF-1 (ng/ml) were measured by ELISA using blood serum collected 
from 3, 6, 12, and 24 week old B6 (white bar) and LY mice (black bar). (Mack and Wood, 
unpublished data)  
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Figure 1.4. TNF signal transduction pathway. TNFa is responsible for the 
inducible expression of genes important for diverse biological processes, including cell 
growth and death, development, oncogenesis, and immune, inflammatory, and stress 
responses. Adapted from (66). 
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Figure 1.5. IGF-1, leptin, Il-6 and TNFa signal transduction pathways. Upon binding 
to their receptors, all activate the protein kinase  signaling. The phosphorylation would 
cause several signal transduction cascades to be activated including (ERK1 and ERK2), 
forkhead box O1 (FOXO1), glycogen synthase kinase 3 (GSK3), Janus kinase (JAK), c-
Jun-N-terminal kinase (JNK). Adapted from (73). 
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Figure 1.6. IL-6 activates the JAK/STAT pathway and the MAPK cascade. IL-6 
binds to plasma membrane receptor complexes containing the common signal 
transducing receptor chain gp 130 (glycoprotein 130). Signal transduction involves the 
activation of JAK (Janus kinase) tyrosine kinase family members, leading to the 
activation of transcription factors of the STAT (signal transducers and activators of 
transcription) family. Another major signalling pathway for IL-6-type cytokines is the 
MAPK (mitogen-activated protein kinase) cascade. Taken from (64).
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Figure1. 7. AP-1 functions in multistep tumorigenesis. AP-1 proteins regulate 
oncogenic transformation, proliferation, apoptosis, invasive growth and angiogenesis 
through modulating the expression of genes. Adapted from (86). 
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CHAPTER 2 
 Regulation of Immediate Early and EMT Markers Genes by IGF-1 in HeLa Cells 
and the Lethal Yellow Mouse Uterus  
Abstract 
IGF-1 can regulate differentiation, apoptosis, cell growth and survival. IGF-1 
levels fluctuate during the development and progression of obesity.  Furthermore, IGF-1 
signaling has been implicated in abnormal cell growth associated with tumorigenesis.  
Thus, these studies suggest a potential link between obesity-induced abnormalities in 
IGF-1 levels and the incidence of cancer. The objective of this study was to identify IGF-
1 dependent changes in the expression of genes that regulate cell proliferation and 
migration.  In this study, HeLa cells were treated with 100ng/ml IGF-1 for 0-24 hour and 
RT-QPCR was carried out using primers against immediate early (IE) genes which 
regulate cell proliferation and differentiation and markers of the epithelial-mesenchymal 
transition (EMT) which promote cell invasion and migration.  IGF-1 stimulated a 
significant transient increase in JUN, FOS, IL-8, IL-6 and CASP10. Furthermore, SNAI1, 
SNAI2 and JAG1 mRNA abundance was significantly increased by IGF-1.  Interestingly, 
we showed that JUN, SNAI1 and SNAI2 mRNA abundance is increased in the uterus of 
our obese mouse model when circulating IGF-1 levels are increased. The signaling 
pathways of AKT, ERK1/2, STAT3, and JNK likely play a role in IGF-1 dependent 
regulation of IE and EMT gene expression.  To assess the activity of IGF-1, cells were 
treated for 0-60 minutes. Western blot analyses demonstrated the increased 
phosphorylation of AKT. Furthermore, IGF-1 dependent phosphorylation of ERK1/2, 
STAT3, and SPAK/JNK occurred at 15min post treatment. Thus, this study has identified 
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a novel mechanism for IGF-1 dependent regulation of cell movement and survival, which 
has important implications for the process of tumorigenesis.  
 
Introduction 
Obesity has been recognized as a national health threat and a major public health 
challenge. Since 1980, over one billion adults considered to be overweight or obese (1) 
(2). In 2007--2008, according to measured weights and heights (3), approximately 72.5 
million adults in the United States were obese (CDC, unpublished data, 2010). Obese 
adults are at increased risk for many diseases, such as coronary heart disease, 
hypertension, stroke, type 2 diabetes, and certain types of cancer.  But the mechanism by 
which obesity increases the risk of cancer is unclear. In obesity, the enlarged amounts of 
adipose tissue results in the distortion of the normal balance of several endogenous 
hormones.  
 
The insulin-like growth factor (IGF-1) 1 is a metabolic hormone that fluctuates 
with nutrient availability.  IGF-1 was once thought to be produced only by the liver and 
dependent on growth hormone (GH) (4). Stimulation of the liver (and other tissues) by 
GH causes the production of IGF-1. Obesity is associated with a decrease in GH. Free 
fatty acids released in response to GH secretion may feedback on the hypothalamus or 
pituitary as a mechanism to limit GH release (5, 6). Numerous investigators have 
observed GH secretion to be diminished in obesity and reversible with weight loss (5, 6).  
In vivo, protein deficiency also decreases IGF-1 levels. Likewise, nutritional repletion 
causes increased IGF-1 production.  It is reported that IGF-1 resistance becomes evident 
in obese individuals similar to insulin and leptin resistance.  Furthermore, in obesity free 
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IGF-1 levels are actually increased in obese men and to a lesser extent in woman, 
suggesting GH-independed changes in IGF-1 synthesis (7). IGF-1 is now known to be 
produced in a wide variety of organs and tissues, especially produced by adipose tissue 
(4). The increased amounts of IGF-I could be secreted from the excessively enlarged 
amounts of adipose tissue (8). In addition, free fatty acids may increased sensitivity to 
feedback effects of IGF-1 or increased free IGF-1 concentrations in obesity (7, 9).  The 
increased free IGF-1 may affect cell growth and development which is related to 
tumorigenesis. The current study suggests a relationship between increased IGF-1 and 
cancer tumorigenesis. 
In the current study, the objective is to identify IGF-1 dependent changes in the 
expression of genes associated with cell transformation and/or migration.  To address this 
objective, two models were used, an immortalized cell line and a mouse model of 
obesity.  HeLa cells are an immortal cell line used in scientific research, including cancer 
research, AIDS, the effects of radiation and toxic substances (10). The HeLa cell which 
was derived from cervical carcinoma, is a good in vitro model for immortal, grows 
indefinitely.   The LY (LY, A
y
/a) mouse has a gene deletion between the promoter and 
first exon region of the agouti gene, which results in ectopic over expression of the agouti 
protein (11, 12).  The over expressed agouti binds to melanocortin-4 receptors (MCR4) as 
an antagonist of -MSH in hypothalamus and in the skin. In hypothalamus, the over 
expressed agouti interferes with normal satiety control and causes over-eating (figure 
2.6.).  In the skin, it results in a yellow coat color. Thus, the LY (LY, A
y
/a) mouse is 
model can be used to mimic the mechanism of obesity development in humans.  
Furthermore, previous data from our lab shows the increased IGF-1 levels in the 6 week 
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old LY mouse compared to the wild-type C57BL/6 control mouse (Mack and Wood, 
unpublished data). With the increased IGF-1 level and overweight, the LY is good vivo 
model which can be used to determine the relationship between obesity dependent 
increasing IGF-1 and the expression of genes associated with cancer tumorigenesis. 
 
 
MATERIALS AND METHODS 
 
 
HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American 
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle’s 
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L 
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L 
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h, 
the cells were changed to the same medium except there was no FBS included for serum 
starvation. After 24h serum starvation, cells were treated with 100ng/ml IGF-1 (Cell 
Signaling Technology, Danvers, MA) for 0, 15, 30 or 60 minutes. The cells were washed 
with 1X HBSS (Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150 
mM NaCl, 1 mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate) 
containing phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini 
Protease Inhibitor Cocktail (Roche Diagnostics).  Cells in the RIPA buffer were sonicated 
15 seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the 
supernatant which contain soluble protein. The protein concentration of each 
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL, 
USA).   
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HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type 
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24 
h as described above. After serum starvation, cells were treated with 100ng/ml IGF-1 
(Sigma, St. Louis, MO) for 0, 0.25, 0.5, 1, 2, 4, 8, 16 or 24 h. The cells were washed with 
1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI reagent (Ambion 
Inc., Austin, TX, USA). Total RNA was extracted according to the manufacturer’s 
protocol (Sigma, St. Louis, MO). After isolation, the total RNA was dissolved in 20 μl 
diethyl pyrocarbonate (DEPC) water. The RNA concentration was determined using 
Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.   
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of 
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water 
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before 
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with 
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA. 
The mixed RNA samples was subsequently combined with 2 μl Random  primers 
(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl 
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples 
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse 
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M 
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The 
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop 
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR. 
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Quantitative, Real-Time PCR (qPCR) Analysis:  Gene-specific forward and 
reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA) 
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C.  The 
information of the primers and probes are shown in table 2.1 and table 2.2. Each set of 
gene-specific primers was tested to determine the maximal concentration of primers that 
could be used to produce specific amplification of the target sequence without primer 
dimer amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3-
phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for 
reverse transcription efficiency and well-to-well variation in template. PCR was 
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City, 
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction 
volume to 20 μl.  QRT-PCR was performed in 364 well plates (Axygen Scientific, Union 
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City, 
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR 
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each 
cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied 
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in 
separate wells in triplicate. These relative values are plotted against the threshold value 
for each dilution to generate a standard curve. An arbitrary value of template was 
assigned to the highest standard and corresponding values were assigned to the 
subsequent dilutions. According to the slope and y-intercept of the standard curve, 
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each 
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experimental and Gapdh triplicate. The value of the average of the experimental triplicate 
divided by the average of the Gapdh triplicate was used for statistical analysis. 
Western Blot Analyses: The protein samples were resolved by SDS-
polyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10% 
separating gel. Protein samples were loaded together with loading buffer and the 
separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA). 
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST 
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20)  for 1 hour with gentle 
shaking in order to block the nonspecific proteins. After that, the blots were probed with 
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The 
membrane was then incubated with primary antibody against phospho-AKT (Cell 
Signaling Technology), phospho-ERK1/2 (Cell Signaling Technology), phospho-JNK, or 
phospho-STAT3 overnight at 4°C with gentle shaking. Blots were washed with 1X TBST 
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted 
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% 
(v/v) Tween 20).  Proteins were incubated with West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific, 
Fairlawn, IL) in dark room.  After the visualization of phosphorylated protein, the blots 
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room 
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked 
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT, 
total ERK1/2, total JNK, or total STAT3 (Cell Signaling Technology) overnight at 4°C 
with gentle shaking.  Total protein was exposed and visualized as described above.  The 
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visualized total protein served as a loading control for each sample. The autoradiograph 
images films were scanned and the density of the protein band was determined in 
Photoshop. Semi-quantitative analysis of band density of the phosphorylated and total 
protein was calculated in each film as described by Miller 
(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html). The 
amount of phosphorylated protein was normalized by total protein expressed in each 
sample. The normalized abundance of phosphorylated protein of each sample was 
subsequently compared to the untreated control sample. The data was showed as a fold-
change. 
Animals: C57BL/6 (B6; C57BL/6 a/a) and Lethal Yellow (LY; C57BL/6 Ay/a) 
female mice were used in the experiment, which the Founder mice were bought from 
Jackson Laboratory (Bar Harbor, ME, USA).  All animal protocols were approved by the 
University of Nebraska Institute of Animal Care and Use Committee (IACUC) according 
to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
According the animal protocols, all the Mice were fed with standard rodent chow and 
fresh water. The mice were housed in cages at virus-free room in a 12/12 hour light/dark 
cycle. Each cage owns no more than 5 mice.  
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism 
4.0 (Graphpad Software, La Jolla, CA). QPCR data and Western blot data were analyzed 
using one-way ANOVA. Differences in data were considered statistically significant at P 
< 0.05. Different letters indicate significant differences in fold change in mRNA 
abundance compared to control for all qPCR data and phospho-protein/total protein ratio 
in time course. The Error bars represent mean  SE.  
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Results 
Significant gene expression differences In HeLa cells  
 To clarify the roles of IGF-1 in the regulation of immediate early genes, HeLa 
cells were treated with 100ng/ml IGF-1 in a time course after 24h serum starvation.  JUN 
mRNA expression was elevated at 2 h compared to untreated control. The mRNA 
expression decreased gradually over time reaching control levels by 24 h. IGF-1 
dependent increase in FOS was maxed at 0.25 hour and began to decrease quickly at 0.5 
hour. For inflammatory response cytokines, IGF1 induced 5-fold increase of IL-8 mRNA 
at 4 h, but the decreased to control level at 16 h. IGF-1 caused fluctuations in MCP-1 and 
IL-6 over the time course evaluate but these changes were not significant.  As an 
important pro-apoptotic factor, caspase 10 mRNA abundance was increased at 4 h to 1.5 
times than control (Fig 2.2).  
 IGF-1 also regulates the mRNA abundance of markers of the epithelial-
mesenchymal transition in HeLa cells (Fig. 2.3). IGF-1 induced mRNA expression level 
of SNAI1 2.5-fold at 2 h, compared to untreated control (Fig 2.3). SNAI2 mRNA was 
also increased by 3-fold but at an earlier time point (at 0.25 hour) and decreased back to 
control level by 1.5 h. IGF-1 did not change mRNA expression of ZEB2 and TWIST1. 
Furthermore, IGF-1 only had a modest effect on JAG1 mRNA abundance at 2-4 h post-
treatment.  
Significant gene expression differences between LY and age matched B6 controls. 
To determine the potential role of altered IGF-1 levels in an obese mouse model 
on immediate early and epithelial-mesenchymal transition marker gene expression, RNA 
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was collected from uterus tissues of lethal yellow (LY) and C57BL/6 (B6) wild-type 
control mice. Fig 2.1 indicated that Snai1, Snai2 and Fos have 1.5-fold increase in 
mRNA abundance in uterus tissues of LY compared to age-matched B6 mice. For Jun, 
mRNA abundance in LY uterus is 2 times higher compared to age-matched B6. 
Signaling Pathways regulated by IGF-1 in HeLa cells 
To further clarify the pathways that potentially mediate IGF-1 effects on the 
immediate early gene expression and epithelial-mesenchymal transition marker gene 
expression, we examined the phosphorylation of AKT and ERK1/2 in untreated and IGF-
1 treated cells. In Fig 2.4., the level of AKT phosphorylation increased dramatically (5-
fold) compared to the untreated control 15 min after the treatment of 100 ng/ml of IGF-1, 
and maintained this fold increase through the 1 hour time point. For ERK1/2, 100 ng/ml 
of IGF-1 induced phosphorylation by 3-fold by15 min, and interestingly, after that, the 
phosphorylation level of ERK dropped back to initial level by 30 minutes post-treatment.  
Fig 2.5 showed that 100 ng/ml of IGF-1 induced phosphorylation of pSAPK/JNK by 3-
fold increase in 15 min, whereas after that, the phosphorylation level dropped back to 
initial level in another 15 minutes,  while pSTAT3,its level increased by 2 fold in 15 
minutes and kept dropping down in another 30 minutes.  
 
Discussion 
FOS and JUN belong to the AP-1 transcription factor family, which is involved in 
a large variety of biological processes such as cell differentiation, proliferation, apoptosis 
and oncogenic transformation. According to Liu's report, AP-1 activities were increased 
in the peritumoral tissue.  AP-1 converts extracellular signals into cell and make changes 
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of expression of specific target genes which harbour AP-1 binding site(s) in their 
promoter or enhancer regions (13-15).   
AP-1 proteins participate in tumorigenesis by regulating oncogenic 
transformation, proliferation, apoptosis, invasive growth and angiogenesis. Fos and FosB 
are dispensable for cell cycle progression, for example, fibroblasts and embryonic stem 
cells have no proliferation defect if lacking these components (16-18). In addition, 
Preston reported the overexpression of c-Fos induces cell death  and resistant to apoptosis 
in an embryonic Syrian hamster cell line (19). However, c-Jun would act as both a 
positive and a negative modulator of apoptosis.  In fact, dependent on its ability to 
heterodimerize with Jun proteins and to bind to DNA, c-Fos acts as oncogenic.  Over-
expressed c-Fos transforms chondroblasts and osteoblasts, and can therefore induce 
tumorigenesis (20, 21). Here, we demonstrated that IGF-1 is able to regulate the 
expression of FOS and JUN in HeLa cells. That the dramatic induction of JUN and FOS 
mRNA level caused by IGF-1, might open a new way to disclose the mechanism that 
IGF-1 uses activator protein 1 (AP-1) to turn on plenty of downstream target genes 
related to the initiation of tumorigenesis.  
In mouse development and tumorigenesis model by Jochum’s, C-Jun binds to the 
promoter of the P53 and Cyclin D1, and then inhibit the p53 gene expression and 
stimulate the cycline D1 gene expression.  C-Fos and FosB also binds to the promoter of 
the CyclinD1 and stimulates the gene expression of CyclinD1 (15).  Furthermore, in our 
mouse model, there is increased blood level of IGF-1 in the LY mouse compared to B6 
mouse (Fig. 1.3). Circulating free IGF-1 levels are actually increased in obese men and to 
a lesser extent in woman (7).   With the increased IGF-1 level and obesity, the LY (LY, 
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A
y
/a) mouse is excellent vivo model for obesity.  The increased IGF-1 could cause the 
unbalanced IGF-1 environment in the LY uterus. Moreover, the qPCR shows the 
increased mRNA expression of Fos in uterus in LY mouse at 6 weeks, which is the onset 
of obesity.  This change is similar as IGF-1 treated in vitro model of HeLa cells. 
Therefore, our data suggest IGF-1’s roles on cell growth, death, and tumorigenesis is 
possibly mediated by AP-1 pathway in obesity, which may suggest a new key to 
understand the relationship between obesity and reproductive tract cancer. 
In our HeLa cells model, IGF-1 is able to induce an important inflammation factor 
IL-8 mRNA level with an increase of 4.5 fold in 4 h. Few data showed this fact. 
Therefore, this is a novel finding.  IL-8 is a chemokine, secreted by macrophages, 
epithelial cells, endothelial cells, also by adipose cells. Increased expression of IL-8 
and/or its receptors has been characterized in cancer cells by its contribution to cancer 
progression and metastasis (22, 23). IL-8 signaling promotes angiogenic responses in 
endothelial cells by increasing proliferation and survival of endothelial and cancer cells, 
and infiltrating neutrophils (22). The IGF-1 related increase of IL-8 increase the risk of 
cancer. Our data indicated that AP-1 subunits mRNA level could be increased by IGF-1 
earlier than did IL-8. Consequently, AP-1 might possibly link a bridge between IGF-1 
and IL-8. 
The epithelial-mesenchymal transition (EMT) occurs not only during normal 
development but also in neoplastic cells which to promote invasion and metastasis (24). 
The snail family, SNAI1 and SNAI2, is important EMT makers.  The zinc-finger 
transcription factor snail induced EMT involved in the invasion and metastasis of 
carcinoma cells during tumorigenesis. Perez-Mancera reported that Snail expression is 
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frequently upregulated in individuals with cancer (25). Our data demonstrated IGF-1 
dependent increase in SNAI1 and SNAI2 mRNA in HeLa cells. Interestingly, there is 
also a significant increase of mRNA expression of   SNAI1 and SNAI2 in LY mouse 
uterus in 6 weeks when compare to the B6 control mouse.  Together with the increased 
IGF-1 level in the 6 week LY mouse, the increased SNAIL family in our vivo and in vitro 
model may show us another key to understand the obesity dependent unbalance IGF-1 
level function in reproductive tract cancer.  
Pro-inflammatory cytokines and hormones released by adipose tissue can 
generate a chronic inflammatory profile which may be associated with Snail protein 
stabilization. In Snail expression knockdown inflammation-mediated breast cancer 
metastasis model, it shows the inhibition of inflammatory cytokines reduced cell 
migration (26, 27). The increased IL-8 related to IGF-1 in HeLa cell may be associated to 
Snail family stabilization. Furthermore, there is a link between Snail expression and AP-
1. In human skin keratinocytes, AP-1 is able to induce SNAIL expression in the exposure 
of Ultraviolet (UV) irradiation (28). Inhibition of AP-1 activity by over-expression of 
dominant-negative c-Jun extremely decreased Snail induction. Analyses of the Snail 
promoter revealed the presence of an AP-1 binding site. EMSA assay demonstrated that 
UV irradiation specifically induced c-Jun binding to this AP-1 site. Mutation of the AP-1-
binding site completely blocked protein binding and inhibited UV irradiation-induced 
Snail promoter activity (27, 28).  Thus, the increased AP-1 expression in obesity may 
cause not only increased tumorigenesis but also increased metastasis due to the AP-1 
induced increase of Snail family protein. Together, these data suggest IGF-1, SNAI1/2 
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and FOS/JUN are important player in obesity and obesity related cancers. Clarification of 
their mechanism provides a promising way for the clinical therapy. 
It is critical to figure out the mediating pathways which transfer IGF-1's signal. 
IGF-I stimulates phosphorylation of the IRS-1 complex , and then cause several signal 
transduction cascades to be activated including the PI3K pathway, which in turn activates 
the AKT pathway (29). Furthermore, low IGF-I decreases cancer due to attenuation of 
AKT and mTOR signaling pathways. Consequently, epidermal response to tumor 
promotion is diminished (29, 30). IGF-1 can stimulate AP-1 and c-jun N-terminal kinase 
(JNK) activation in retina according to Poulaki report (31).  Using systemic inhibition of 
IGF-I signaling with a receptor-neutralizing antibody, or with inhibitors of PI-3 kinase 
(PI-3K), c-Jun kinase (JNK), or AKT, it shows a suppressed retinal AKT, JNK and AP-1 
activity. In addition, intravitreous administration of IGF-I increased retinal AKT, JNK 
and AP-1 activity (31). Our western-blot data demonstrated that IGF-1 is sufficient to 
activate AKT, ERK, JNK, and STAT immediately at 15 minutes which is same as the 
report by Taniguchi. This provides a clue that AKT, ERK, JNK, and STAT are mediator 
to deliver IGF-1 signal to increase some downstream target gene expression, including 
regulation of IE and EMT gene expression.  In the screening through chemical 
inhibitors, Snail induction is reduced by inhibitors of ERK and JNK. 
IGF-1 is one of the important unbalanced hormones in obesity. While there are 
reports about decreased circulating IGF-1 levels or no difference in IGF-1 levels between 
obese and normal-weight individuals, our lab’s in vivo study show circulating levels of 
IGF-1 were significantly increased in the LY compared to B6 controls at 6 weeks. 
Together with the vitro data with IGF-1 treatment in HeLa cells, this study has identified 
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a novel mechanism for important relationship between obesity dependent IGF-1 and 
reproductive tract cancer. It is may be another key to understand a plausible mechanism 
for obesity-dependent increases in cancers of the female reproductive tract.   
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Table 2.1. Human Primer sequences used for QPCR analysis 
 
Gene Probe  
Dye  
 
Primer Sequence (5' to  3') 
CASP10 SYBR Green  
 
Forward GGAGCTGTCTACTCTTCGGATGA 
Reverse AGGGCTGTGAAGTGAGACATGAT 
FOS SYBR Green  
 
Forward CCTCGCCCGGCTTTG 
Reverse GCCTCGTAGTCTGCGTTGAAG 
JUN SYBR Green  
 
Forward CTGGGAGGACCGGAGACA 
Reverse GAGAAGCCTAAGACGCAGGAAA 
MCP-1 SYBR Green  
 
Forward CAAGCAGAAGTGGGTTCAGGAT 
Reverse TCTTCGGAGTTTGGGTTTGC 
IL-6 SYBR Green  
 
Forward AGGGCTCTTCGGCAAATGTA 
Reverse GAAGGAATGCCCATTAACAACAA 
IL-8 SYBR Green  
 
Forward CTGGCCGTGGCTCTCTTG 
Reverse CCTTGGCAAAACTGCACCTT 
SNAI1 SYBR Green  
 
Forward CCCCAATCGGAAGCCTAACT 
Reverse GCTGGAAGGTAAACTCTGGATTAGA 
SNAI2 SYBR Green  
 
Forward CCTGGGCGCCCTGAA 
Reverse TTCTCCCCCGTGTGAGTTCT 
TWIST1 SYBR Green  
 
Forward TCCGCGTCCCACTAGCA 
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC 
ZEB2 SYBR Green  
 
Forward CCAGCTCGAGCGGCATA 
Reverse GCCACACTCTGTGCATTTGAA 
JAG1 SYBR Green  
 
Forward CAGCTCTGTGACAAAGATCTCAATTAC 
Reverse AGGGCCTGTGTTGCTACAAGTT 
GAPDH Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems  
(VIC Probe) 
 
Table 2.2. Mouse  Primer sequences used for QPCR analysis 
 
Gene Probe  
Dye  
 
Primer Sequence (5' to  3') 
Fos SYBR Green  
 
Forward CCCCAAACTTCGACCATGAT 
Reverse GGAGGATGACGCCTCGTAGTC 
Jun SYBR Green  
 
Forward CCGCCCCTGTCCCCTAT 
Reverse TCCTCATGCGCTTCCTCTCT 
Snai1 SYBR Green  
 
Forward GCCTGTGCCCGAACCTT 
Reverse GCCAGACTCTTGGTGCTTGTG 
Snai2 SYBR Green  
 
Forward GCCTGGGTGCCCTGAAG 
Reverse TTGCAGACACAAGGCAATGTG 
Gapdh 
 
Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems  
(VIC Probe) 
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Figure 2.6. Lethal yellow mouse model. The LY mouse own a gene deletion in the 
promoter and first exon region of the agouti gene which locus on the C57BL/6 
background.  The deletion causes the ubiquitous expression of the agouti gene. Over-
expressed agouti acts as an antagonist of a-MSH by binding to melanocortin-4 receptors 
(MCR4) in the hypothalamus. Therefore, over-expressed agouti protein interfers with 
normal satiety control. As a consequence, the LY mice overeat resulting in the 
development of obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
Literature Cited 
 
1. VanItallie TB 1994 Worldwide epidemiology of obesity. Pharmacoeconomics 
5:1-7 
2. Loos RJF, Bouchard C 2003 Obesity - is it a genetic disorder? Journal of Internal 
Medicine:401-425 
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR Prevalence and trends in obesity 
among US adults, 1999-2008. JAMA 303:235-241 
4. Peter MA, Winterhalter KH, Boni-Schnetzler M, Froesch ER, Zapf J 1993 
Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by 
growth hormone in rat white adipose tissue. Endocrinology 133:2624-2631 
5. Glass AR, Burman KD, Dahms WT, Boehm TM 1981 Endocrine function in 
human obesity. Metabolism 30:89-104 
6. Strobl JS, Thomas MJ 1994 Human growth hormone. Pharmacol Rev 46:1-34 
7. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H 1995 Free insulin-
like growth factors in human obesity. Metabolism 44:37-44 
8. Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh 
KB 1995 Acipimox potentiates growth hormone (GH) response to GH-releasing 
hormone with or without pyridostigmine by lowering serum free fatty acid in 
normal and obese subjects. J Clin Endocrinol Metab 80:2495-2498 
9. Smith SR 1996 The endocrinology of obesity. Endocrinol Metab Clin North Am 
25:921-942 
10. Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, 
Popescu N, Ried T 1999 Comprehensive and definitive molecular cytogenetic 
characterization of HeLa cells by spectral karyotyping. Cancer Res 59:141-150 
11. Bultman SJ, Michaud EJ, Woychik RP 1992 MOLECULAR 
CHARACTERIZATION OF THE MOUSE AGOUTI LOCUS. Cell 71:1195-
1204 
12. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP 1995 ECTOPIC 
EXPRESSION OF THE AGOUTI GENE IN TRANSGENIC MICE CAUSES 
OBESITY, FEATURES OF TYPE-II DIABETES, AND YELLOW FUR. 
Proceedings of the National Academy of Sciences of the United States of America 
92:4728-4732 
13. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D 
2002 Activation of NF-kappa B, AP-1 and STAT transcription factors is a 
frequent and early event in human hepatocellular carcinomas. J Hepatol 37:63-71 
14. Jochum W, Passegue E, Wagner EF 2001 AP-1 in mouse development and 
tumorigenesis. Oncogene 20:2401-2412 
15. Shaulian E, Karin M 2001 AP-1 in cell proliferation and survival. Oncogene 
20:2390-2400 
16. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J 1995 Repression of the 
retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, 
wt1. Oncogene 10:1125-1129 
17. Schreiber M, Wang ZQ, Jochum W, Fetka I, Elliott C, Wagner EF 2000 Placental 
vascularisation requires the AP-1 component fra1. Development 127:4937-4948 
 59 
18. Gruda MC, van Amsterdam J, Rizzo CA, Durham SK, Lira S, Bravo R 1996 
Expression of FosB during mouse development: normal development of FosB 
knockout mice. Oncogene 12:2177-2185 
19. Preston GA, Lyon TT, Yin Y, Lang JE, Solomon G, Annab L, Srinivasan DG, 
Alcorta DA, Barrett JC 1996 Induction of apoptosis by c-Fos protein. Mol Cell 
Biol 16:211-218 
20. Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF 1993 Osteoblasts are target 
cells for transformation in c-fos transgenic mice. J Cell Biol 122:685-701 
21. Ruther U, Komitowski D, Schubert FR, Wagner EF 1989 c-fos expression 
induces bone tumors in transgenic mice. Oncogene 4:861-865 
22. Waugh DJ, Wilson C 2008 The interleukin-8 pathway in cancer. Clin Cancer Res 
14:6735-6741 
23. Yuan A, Chen JJ, Yao PL, Yang PC 2005 The role of interleukin-8 in cancer cells 
and microenvironment interaction. Front Biosci 10:853-865 
24. Yang J, Weinberg RA 2008 Epithelial-mesenchymal transition: at the crossroads 
of development and tumor metastasis. Dev Cell 14:818-829 
25. Perez-Mancera PA, Perez-Caro M, Gonzalez-Herrero I, Flores T, Orfao A, de 
Herreros AG, Gutierrez-Adan A, Pintado B, Sagrera A, Sanchez-Martin M, 
Sanchez-Garcia I 2005 Cancer development induced by graded expression of 
Snail in mice. Hum Mol Genet 14:3449-3461 
26. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP 2009 Stabilization of 
snail by NF-kappaB is required for inflammation-induced cell migration and 
invasion. Cancer Cell 15:416-428 
27. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, 
Savagner P 2006 Snail and slug play distinct roles during breast carcinoma 
progression. Clin Cancer Res 12:5395-5402 
28. Li Y, Liu Y, Xu Y, Voorhees JJ, Fisher GJ UV irradiation induces Snail 
expression by AP-1 dependent mechanism in human skin keratinocytes. J 
Dermatol Sci 60:105-113 
29. Taniguchi CM, Emanuelli B, Kahn CR 2006 Critical nodes in signalling 
pathways: insights into insulin action. Nature reviews 7:85-96 
30. Moore T, Carbajal S, Beltran L, PERKins SN, Yakar S, Leroith D, Hursting SD, 
Digiovanni J 2008 Reduced susceptibility to two-stage skin carcinogenesis in 
mice with low circulating insulin-like growth factor I levels. Cancer Res 68:3680-
3688 
31. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP 2004 
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am 
J Pathol 165:457-469 
 
 
 
 
60 
CHAPTER 3 
 Regulation of Immediate Early and EMT Markers by leptin in HeLa Cells 
Abstract 
Obesity increases the risk factor in various cancers including breast, endometrial, 
ovarian, prostate cancer esophagus, gastric, colon cancer, leukemias. Leptin acts as 
significant role in the pathophysiology of obesity. Given that, the increased leptin level in 
obese individuals, the study suggests the relationship of leptin’s link to cancer risk is of 
such considerable importance. In the current study, after 24h serum starvation, HeLa cells 
were treated with 100ng/ml leptin for 0, 0.5,1,2,4 or 8 hours. After treatment, RNA was 
collected and quantitative PCR (QPCR) was carried out using primers against immediate 
early (IE) genes JUN, FOS, IL-8, IL-6, MCP-1 and CASP10 and epithelial-mesenchymal 
transition (EMT) marker genes SNAI1, SNAI2, Twist, CDH1, ZEB2. Leptin stimulated a 
significant transient increase in JUN, IL-6 and MCP-1 with the peak showing at 8 hour. 
The signaling pathways including ERK1/2, STAT3, and SAPK/JNK is important for the 
regulation of the IE and EMT. Western blot analyses demonstrated increased 
phosphorylation of STAT3, and SAPK/JNK by leptin in HeLa cells.  In all, this study has 
identified a novel mechanism for important relationship between leptin and cancer in 
obesity. It may be another key to understand cancer and provide new methods to care 
cancer.  
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Introduction 
Obesity is a prevalent condition which is often stigmatized. Nearly two-thirds of 
the United States population is overweight. Since 1980, more than one-third of the 
population are at least 20% above their normal weight in the USA, and this proportion is 
increasing (3, 4). Increasingly, obesity has become a serious medical problem in 
developing nations with urbanization and a more plentiful food supply. However, obesity 
is not just meaning too much fat,  in fact, it reduce life expectancy is reduced when body-
mass index (BMI, body mass index) is 20% or more above normal (1). Furthermore, 
obesity  is followed with the increased likelihood of various diseases, including  heart 
disease, type 2 diabetes,  high blood pressure, weight-bearing arthritis , asthma  and 
certain types of cancers (2).  
In individuals, energy balance is normally controlled by a feedback loop which 
interacts with the satiety center in the brain, which maintains constancy of total body 
energy stores. In the obese phenotype, there is an increase in plasma leptin suggesting 
that obesity results in resistance to leptin and disruption of satiety control which further 
exacerbates the obesity.  In recent years, leptin has become a focus for obesity-dependent 
diseases because the key role to balance energy intake.  
Leptin is from the Greek word "leptos," meaning thin.  It is a peptide hormone of 
16kDa and 167 amino acids; one of the important adipose derived hormones which 
regulates energy intake and expenditure. Leptin is the product of the "obesity" (ob) gene 
which is discovered in 1994 by Zhang (5). In an individual, leptin is expressed primarily 
by the adipocytes of white adipose tissue and, at lower levels, in gastric epithelium and 
placenta (6, 7). In the central nervous system, leptin interacts with the complex pathways 
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and also through direct peripheral mechanisms. Leptin acts as a mediator of energy 
expenditure (8); as a permissive factor to mediate puberty (9); as a signal of metabolic 
status during pregnancy to modulate the fetus and the maternal metabolism (10); and as a 
mediator to interact with other hormones to regulate the energy status and metabolism 
including insulin, the insulin-like growth factors, growth hormone and glucocorticoids 
(11-13). Leptin was considered as a great hope to be the successful treatment of obesity 
for scientific and clinical communities. But it is just a dream to use leptin to treat obesity. 
The complex leptin axis and the existence of leptin resistance in most obesity make the 
dream gone with wind.  However the role of the leptin axis is now being shown to have 
more functions than it was first discovered.  Complex interactions between hormone axes 
in the periphery are integral in maintaining homeostasis of a diverse range of functions.  
 Though obesity is recognized as an established risk factor in various cancers; it is 
only recently that studies have established a link between leptin and cancer. For example, 
leptin was reported to play an important role in serious human reproduction cancers such 
as breast, endometrial, ovarian and prostate cancer (14-17). Leptin promotes the growth 
of malignant cells by activating signal transducer and activator of transcription 3 
(STAT3) and kinase (ERK) 1/2 pathways in breast cancer (18).  Leptin might be a 
potential regulator for ovarian cancer, as leptin receptors were identified in ovarian 
surface epithelium and ovarian cancer cell lines (16). Obesity, a situation characterized 
by high levels leptin, has also been examined as a potential increased risk factor for 
prostate cancer but there is no clear evidence to support a strong pathogenic link between 
obesity and prostate cancer (17, 19).  However, leptin may cause the alterations of the 
balance of sexual hormones, which result in increased risk of prostate cancer (17, 19).  In 
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all, leptin could be one of the important key to determine the reason of the increased risk 
of cancer in obesity. 
 
MATERIALS AND METHODS 
 
 
HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American 
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle’s 
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L 
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L 
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h, 
the cells were changed to the same medium except there was no FBS included for serum 
starvation. After 24h serum starvation, cells were treated with 100ng/ml leptin (Sigma, 
St. Louis, MO) for 0, 15, 30 or 60 minutes. The cells were washed with 1X HBSS 
(Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150 mM NaCl, 1 
mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate) containing 
phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini Protease 
Inhibitor Cocktail (Roche Diagnostics).  Cells in the RIPA buffer were sonicated 15 
seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the 
supernatant which contain soluble protein. The protein concentration of each 
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL, 
USA).   
HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type 
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24 
hours as described above. After serum starvation, cells were treated with 100ng/ml leptin 
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(Sigma, St. Louis, MO) for 0, 0.25, 0.5, 1, 2, 4, or 8 hours. The cells were washed with 
1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI reagent (Ambion 
Inc., Austin, TX, USA). Total RNA was extracted according to the manufacturer’s 
protocol (Sigma, St. Louis, MO). After isolation, the total RNA was dissolved in 20 μl 
diethyl pyrocarbonate (DEPC) water. The RNA concentration was determined using 
Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.   
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of 
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water 
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before 
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with 
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA. 
The mixed RNA samples was subsequently combined with 2 μl Random  primers 
(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl 
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples 
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse 
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M 
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The 
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop 
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR. 
Quantitative, Real-Time PCR (qPCR) Analysis:  Gene-specific forward and 
reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA) 
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C.  The 
information of the primers and probes are shown in table 3.1. Each set of gene-specific 
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primers was tested to determine the maximal concentration of primers that could be used 
to produce specific amplification of the target sequence without primer dimer 
amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3-
phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for 
reverse transcription efficiency and well-to-well variation in template. PCR was 
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City, 
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction 
volume to 20 μl.  QRT-PCR was performed in 364 well plates (Axygen Scientific, Union 
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City, 
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR 
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each 
cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied 
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in 
separate wells in triplicate. These relative values are plotted against the threshold value 
for each dilution to generate a standard curve. An arbitrary value of template was 
assigned to the highest standard and corresponding values were assigned to the 
subsequent dilutions. According to the slope and y-intercept of the standard curve, 
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each 
experimental and Gapdh triplicate. The value of the average of the experimental triplicate 
divided by the average of the Gapdh triplicate was used for statistical analysis. 
Western Blot Analyses: The protein samples were resolved by SDS-
polyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10% 
separating gel. Protein samples were loaded together with loading buffer and the 
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separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA). 
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST 
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20)  for 1 hour with gentle 
shaking in order to block the nonspecific proteins. After that, the blots were probed with 
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The 
membrane was then incubated with primary antibody against phospho-AKT (Cell 
Signaling Technology, Danvers, MA), phospho-ERK1/2 (Cell Signaling Technology), 
phospho-SAPK/JNK (Cell Signaling Technology), or phospho-STAT3 (Cell Signaling 
Technology) overnight at 4°C with gentle shaking. Blots were washed with 1X TBST 
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted 
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% 
(v/v) Tween 20).  Proteins were incubated with West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific, 
Fairlawn, IL) in dark room.  After the visualization of phosphorylated protein, the blots 
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room 
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked 
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT, 
total ERK1/2, total SAPK/JNK, or total STAT3 (Cell Signaling Technology) overnight at 
4°C with gentle shaking.  Total protein was exposed and visualized as described above.  
The visualized total protein served as a loading control for each sample. The 
autoradiograph images films were scanned and the density of the protein band was 
determined in Photoshop. Semi-quantitative analysis of band density of the 
phosphorylated and total protein was calculated in each film as described by Miller 
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(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html). The 
amount of phosphorylated protein was normalized by total protein expressed in each 
sample. The normalized abundance of phosphorylated protein of each sample was 
subsequently compared to the untreated control sample. The data was showed as a fold-
change. 
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism 
4.0 (Graphpad Software, La Jolla, CA). QPCR data and western-blot data were analyzed 
using one-way ANOVA. Differences in data were considered statistically significant at P 
< 0.05. Different letters indicate significant differences in fold change in mRNA 
abundance compared to control for all qPCR data and phospho-protein/total protein ratio 
in time course. The Error bars represent mean  SE.  
 
Results 
Significant gene expression differences In HeLa cells by Leptin 
To evaluate effects of leptin on the immediate early gene expression, HeLa cells 
were treated with 100 ng/ml leptin after 24-hour serum starvation.  The abundance of 
each mRNA transcript was analyzed by quantitative real-time PCR (qPCR).  These 
analyses indicated that JUN ,FOS , IL-8 and CASP10 are modestly increased 0.5 hours 
after leptin treatment, although statistically insignificant, as compared to control. MCP-1 
and IL-6 began to show a trend of increased mRNA at 0.5 hour. At 8 hours, their mRNA 
increased significantly by 1.5- and 2-fold, respectively compared to untreated control 
cells (Fig 3.1).  Conversely, 100 ng/ml of leptin had no effect on mRNA level of 
epithelial-mesenchymal transition marker gene expression, including SNAI1, SNAI2, 
Twist, ZEB2, and JAG1. There is no significant difference in mRNA abundance 
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compared to untreated control cells at any time point (Fig. 3.2). 
 
Signaling Pathways regulated by leptin in HeLa cells 
ERK1/2 and JNK-STAT pathways are important mediators of leptin effects on 
cell function. In Fig 3.3, 100 ng/ml of leptin only had a modest effect on the 
phosphorylation of ERK1/2 over the time course. Specifically, phosphorylated ERK1/2 
was increased by 1.5 fold in 15 minutes. In Fig 3.4, leptin increased SAPK/JNK and 
STAT3 phosphorylation by 1.5- or 2- fold, respectively as early as 15 minutes after 
treatment. After that, SAPK/JNK phosphorylation began to decrease toward untreated 
control levels, but increased STAT3 phosphorylation level was maintained over the entire 
time course. 
 
Discussion 
Obesity, characterized by high levels of leptin, has also been examined as a potential 
increased risk factor for cancer but there is no clear evidence to support a strong pathogenic link 
between leptin and cancer.   However, leptin cause the alterations of the balance of sexual 
hormones, which result in increased risk of prostate cancer (17, 19). Leptin was reported to 
play an important role in a serious human reproduction cancer such as breast, 
endometrial, ovarian and prostate cancer (14-17). Recently, more and more attentions 
were focused on unbalance hormone level in obesity, such as leptin. The leptin levels, 
which play an important role in obesity , were compared between LY and B6 males and 
females (20, 21). According to the previous data of our lab, leptin levels were 
significantly increased in LY female mice compared to age-matched controls at both 12 
and 24 weeks of age.  
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To determine potential mechanisms for obesity-induced cancer, HeLa cells were 
treated with leptin in this study.  Our data demonstrated that leptin increased the 
expression of inflammation genes MCP-1 and IL-6 at 8 hours. It was reported previously 
that leptin induced the expression of IL-6 and MCP-1 in obese mice and lean Wistar Rats 
(22, 23).  Our study similarly showed leptin-dependent increase in IL-6 and MCP-1 
expression although the induction magnitude was not as great and likely reflects 
differences between chronic and acute exposure to leptin. In addition, 
advanced/metastatic cancer patients have higher levels of IL-6 in their blood (24).  There 
is an elevated levels of IL-6 in murine models of colitis-associated cancer (CAC) (25) 
and the higher serum levels of IL-6 exhibited in males could be the reason of gender bias 
in liver cancer susceptibility (26).  IL-6 promotes the in vivo growth of tumors in models 
of prostate, breast, and lung cancers (27). The increased IL-6 may be the important link 
between increased leptin and obesity related cancer. In fact, obesity is associated with a 
chronic inflammatory response characterized by over expressed cytokine such as IL-6 , 
TNF , inhibitor of NF- B kinase b (IKKb), macrophage migration inhibitory factor, 
nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor 1 
and haptoglobin; increased acute-phase reactants, and activation of inflammatory 
signaling pathways (28, 29).  
Increased IL-6 and MCP-1 play very important roles in obese mice. Interestingly, 
IL-6 has pro-inflammatory and anti-inflammatory function. IL-6 is secreted by immune 
cells including T cells and macrophages in response to foreign pathogen stimulus, in 
order to activate inflammation (22, 23).   Thus, the increased leptin may play a role to 
induce the micro-inflammatory condition in obesity. In fact, adipocytes are able to 
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produce IL-6, as reported that endogenous CRP level is very high in obese individuals 
(30). The inflammatory conditions in obesity may initiate or promote oncogenic 
transformation, and also can generate an inflammatory microenvironment that promotes 
tumor progression.  MCP-1, is a small cytokine that functions as recruitment of 
monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, and 
inflammation. MCP-1 acts as chemotactic activity for monocytes and basophils but not 
for neutrophils or eosinophils (31). Interestingly, many tumors are reported to produce 
abundant MCP-1, including melanoma (32), ovarian cancer (33), and breast carcinoma 
(34). Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.  
In the current study, leptin did not affect FOS/JUN expression in 4 hours. While 
in 8 hours, JUN mRNA appeared to be up-regulated. Jun, in combination with c-Fos, is 
required for the increased activity at AP-1 promoters. AP-1 activity depends on both 
double phosphorylations by the JNK pathway, and phosphorylation-independent 
pathway. AP-1 proteins participate in tumorigenesis by regulating oncogenic 
transformation, proliferation, apoptosis, invasive growth and angiogenesis (35). c-Jun 
protein was established as an oncogene at the early stage of hepatocellular carcinoma in a 
mouse mode (36). In mice with c-Jun deletion, the number and size of hepatic tumors 
were reduced. This process was related to increased p53 level and apoptosis (36). In 
mouse development and tumorigenesis model by Jochum’s, c-Jun binds to the promoter 
of the P53 and cyclin D1, and then inhibit the p53 gene expression and stimulate the 
cycline D1 gene expression (37). Inhibition of AP-1 activity by over-expressing a 
dominant negative form of cJun (cjun-DN, Tam67) inhibits breast cancer cell growth. 
Targeting the AP-1 transcription factor may be a key for the treatment of breast cancer 
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(38, 39).  Our data indicated leptin was able to increase JUN mRNA level in HeLa cells. 
This suggests that JUN inhibition provides a promising therapeutic method for obesity 
related cancer.   However, we didn't find leptin was able to regulate the expression of 
epithelial transition marker genes, including SNAI1/2, ZEB2, TWIST1, or JAG1 at early 
hours in HeLa cells.  
To seek for the early mediators which deliver leptin signaling, we demonstrated 
that leptin was able to activate ERK1/2, JNK-STAT early at 15 minutes. Some studies 
showed that leptin increased cancer cell growth through the ERK1/2 and JNK-STAT 
pathway, increased cancer cell invasion via a PI-3K. In addition, the nuclear expressions 
of ERK1/2 might be useful markers for tumor invasiveness and lymph node metastasis in 
stomach cancer. Leptin promotes the growth of malignant cells by activating signal 
transducer and activator of transcription 3 (STAT3) and kinase (ERK) 1/2 pathways in 
breast cancer (46).  ERK pathway is activated by a variety of stimuli including growth 
factors, cytokines, virus infection, and carcinogens. It has been reported that leptin 
markedly activated ERKs and JNK. In contrast, these stimulatory effects of leptin on 
ERKs and JNK were completely inhibited by a PKC inhibitor Ro 32-0432 as well as 
EDTA. In this process, Ca2+-independent novel PKC provides a link between leptin and 
ERKs/JNK (47).These results provide an appropriate explanation on our finding. 
ERKs pathway activates Fos and Jun, resulting in activation of AP-1. The 
transcriptional activity of c-Fos is regulated by phosphorylation at Ser374 by ERK.  JNK 
also activates C-FOS via activation of ERK-1. JNK phosphorylates c-Jun at Ser63 and 
Ser
73
(48, 49).  STAT signaling is essential for the regulation of food intake and energy 
expenditure by leptin. Binding of leptin to its receptor stimulates gene transcription via 
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activation of STAT proteins. In Ishikawa cells, leptin was reported to increase STAT3-
DNA binding activity to Cyclin D1 promoter, enhance recruitment of STAT3 to the 
promoter region of cyclin D1 (50). In contrast, STAT3 knockdown prevented leptin-
induced cyclin D1 expression and cell proliferation (50). Our data show the increased 
phosphorylation of STAT3 though it is not significant. All of these data suggested a 
strong link between leptin and tumor progression. However, the precise network between 
leptin and ERK, JNK, and STAT pathway activation remain unclear. Further studies will 
be needed to clarify these questions. 
In summary, our data also indicated that both leptin and IL-6/MCP-1 activated 
STAT3. Therefore, IL-6/MCP-1-STAT3 axis is a potential important pathway in obesity-
dependent cancers. In addition, there is an interest in developing anti-IL-6/MCP-1 agents 
as therapy against obesity and cancers.  
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Table 3.1. Human  Primer sequences used for QPCR analysis 
 
 
Gene Probe  
Dye  
 
Primer Sequence (5' to  3') 
CASP10 SYBR Green  
 
Forward GGAGCTGTCTACTCTTCGGATGA 
Reverse AGGGCTGTGAAGTGAGACATGAT 
FOS SYBR Green  
 
Forward CCTCGCCCGGCTTTG 
Reverse GCCTCGTAGTCTGCGTTGAAG 
JUN SYBR Green  
 
Forward CTGGGAGGACCGGAGACA 
Reverse GAGAAGCCTAAGACGCAGGAAA 
MCP-1 SYBR Green  
 
Forward CAAGCAGAAGTGGGTTCAGGAT 
Reverse TCTTCGGAGTTTGGGTTTGC 
IL-6 SYBR Green  
 
Forward AGGGCTCTTCGGCAAATGTA 
Reverse GAAGGAATGCCCATTAACAACAA 
IL-8 SYBR Green  
 
Forward CTGGCCGTGGCTCTCTTG 
Reverse CCTTGGCAAAACTGCACCTT 
SNAI1 SYBR Green  
 
Forward CCCCAATCGGAAGCCTAACT 
Reverse GCTGGAAGGTAAACTCTGGATTAGA 
SNAI2 SYBR Green  
 
Forward CCTGGGCGCCCTGAA 
Reverse TTCTCCCCCGTGTGAGTTCT 
TWIST1 SYBR Green  
 
Forward TCCGCGTCCCACTAGCA 
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC 
ZEB2 SYBR Green  
 
Forward CCAGCTCGAGCGGCATA 
Reverse GCCACACTCTGTGCATTTGAA 
JAG1 SYBR Green  
 
Forward CAGCTCTGTGACAAAGATCTCAATTAC 
Reverse AGGGCCTGTGTTGCTACAAGTT 
GAPDH Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems  
(VIC Probe) 
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CHAPTER 4 
Regulation of Immediate Early and EMT Markers Genes by Pro-
inflammatory cytokines in HeLa Cells 
 
ABSTRACT 
Obesity is associated with a chronic inflammatory response characterized by over-
expression of cytokines including TNFα and IL-6. Thus, there may be an important 
relationship between abnormal chronic cytokine levels and cancer risk. To determine the 
role of TNFα and IL-6 on the expression of genes associated with increased cancer risk in 
obesity, HeLa cells were treated with IL-6 or TNFα for 0-8 hours. Quantitative, real-time 
RT-PCR was carried out using primers against immediate early (IE) genes JUN, FOS, IL-
8, IL-6, MCP-1, and CASP10; and epithelial-mesenchymal transition (EMT) marker 
genes SNAI1, SNAI2, Twist, JAG1, and ZEB2. IL-6 stimulated a significant transient 
increase in FOS, IL-8 and MCP-1. Interestingly, IL-6 also increased the gene expression 
of IL-6 in HeLa cells. Furthermore, SNAI1 mRNA abundance was significantly 
increased by IL-6. Likewise TNFα treatment caused a transient increase in JUN, FOS, 
IL-6 and IL-8. To assess more information of the activity of IL-6 and TNFα, Western blot 
analyses were carried out to study phosphorylation of ERK1/2, STAT3, and SAPK/JNK.  
Both IL-6 and TNF  stimulated phosphorylation of SAPK/JNK ERK1/2 and STAT3.  In 
all, this study has identified a novel mechanism for important relationship between IL-6, 
TNFα and cancer risk in obesity. It would be another key to provide new method to care 
and prevent cancer.  
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INTRODUCTION 
Too much adipose tissue in obesity is not only characterized by increased 
hormone level, but also with macrophage infiltration which are an important source of 
inflammation in this tissue. In fact, obesity is associated with a chronic inflammatory 
response characterized by over expressed cytokines such as IL-6 ,TNFα, inhibitor of NF-
B kinase b (IKKb), macrophage migration inhibitory factor, nerve growth factor, 
vascular endothelial growth factor, plasminogen activator inhibitor 1 and haptoglobin; 
increased acute-phase reactants, and activation of inflammatory signaling pathways (1, 2) 
Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF ) are multifunctional 
cytokines involved in the regulation of the immune response, hematopoiesis, and 
inflammation. IL-6 is produced by numerous types of immune or immune accessory 
cells, such as monocytes, fibroblasts, lymphocytes, and glial cells. It is also produced by 
nonimmune cells such as adipose cells (5). Tumor necrosis factor alpha (TNF ) is a 26-
kDa transmembrane protein that is cleaved into a 17-kDa biologically active protein that 
exerts its effects via type I and type II TNFα receptors. TNF  is a member of a group of 
cytokines involved in systemic inflammation and is a multifunctional cytokine playing a 
role in apoptosis, cell survival, inflammation and immunity. TNF plays an important 
role in cancer, such as “cachectin” and T-lymphocyte differentiation factor (3, 4). In fact, 
TNF  also is able to inhibit tumorigenesis and viral replication.  
At the beginning, IL-6 and TNFα were thought to be products of the immune 
system alone that had immune functions only. Yet, it has become increasingly apparent 
that the cytokines involving in both the nervous and endocrine systems. IL-6 and,TNFα 
have been shown to have endocrine as well as autocrine and paracrine roles. IL-6 is a 
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pleiotropic cytokine with many pathophysiologic roles in humans (6), which has drawn 
much attention in the endocrine field including those studying the endocrine properties of 
adipose tissue. Adipose tissue is recognized as endocrine organ to express and secrete a 
variety of bioactive peptides, known as adipokines including IL-6, TNFα, adiponectin, 
and leptin, which act at both the local (autocrine/paracrine) and systemic (endocrine) 
level (1, 2, 7). In adipose tissue, TNFα is produced by adipocytes and stromovascular 
cells (8). In fact, obesity is characterized chronic mild inflammation, with increased 
circulating levels of inflammatory cytokine and the expression and release of 
inflammation-related adipokines (1).  Recently, it has been shown that IL-6 and TNFα are 
both produced by the adipose tissue (5, 9), suggesting that they may play a key roles in 
lipid metabolism. 
Cytokines are known to have both tumor-promoting and inhibitory effects on 
breast cancer growth depending presumably on their relative concentrations and the 
presence of other modulating factors (10).  These bioactive peptides  produced the 
adipose cell promote angiogenesis including vascular endothelial growth factor, 
hepatocyte growth factor, leptin, tumour necrosis factor-alpha, heparin-binding epidermal 
growth factor-like growth factor, and interleukin-6 (11). It is well known that there is an 
increased cancer risk by obesity and there is growing evidence that tumors are sustained 
and promoted by inflammatory signals from the surrounding microenvironment. Together 
with the unbalance of hormones and factors which are produced by the adipose cells in 
obesity, there may have a link between the adipose cells produced pro-inflammatory 
cytokine and the increased risk of cancer. IL-6 and TNFα may play the key role in 
increased cancer risk in obesity.  
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Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and 
tumor-inhibitory effects (10). Knüpfer has reported that, IL-6 would be a negative 
prognosticator in breast tumor patients concerning patients‟ serum IL-6 levels (10). 
Grivennikov and Bollrath demonstrated that the importance of the interleukin-6 family of 
proinflammatory cytokines and their downstream effector STAT3 in colitis-associated 
colon cancer (12, 13). Moreover, TNFα acts as a multifunctional cytokine to involve in 
apoptosis, cell survival, inflammation, and immunity (14, 15). Recently, TNFα is used in 
the regional treatment of locally advanced soft tissue sarcomas and metastatic melanomas 
and other tumors (16). 
In all, the pro-inflammatory cytokine IL-6 andTNFα would be a new key to 
understand the link between obesity and cancer.  We need to drew more attention to the 
relationship between pro-inflammatory cytokine and cancer, such as IL-6 andTNFα in 
obesity 
 
MATERIALS AND METHODS 
 
 
HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American 
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle‟s 
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L 
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L 
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h, 
the cells were changed to the same medium except there was no FBS included for serum 
starvation. After 24h serum starvation, cells were treated with 10 ng/ml interleukin-6 
(Cell Signaling Technology, Danvers, MA) or 10 ng/ml TNF   (Cell Signaling 
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Technology, Danvers, MA) for 0, 15, 30 or 60 minutes. The cells were washed with 1X 
HBSS (Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150 mM 
NaCl, 1 mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate) 
containing phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini 
Protease Inhibitor Cocktail (Roche Diagnostics).  Cells in the RIPA buffer were sonicated 
15 seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the 
supernatant which contain soluble protein. The protein concentration of each 
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL, 
USA).   
HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type 
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24 
hours as described above. After serum starvation, cells were treated with 10 ng/ml IL-6 or 
10 ng/ml TNF  (Cell Signaling Technology) for 0, 0.25, 0.5, 1, 2, 4, or 8 hours. The cells 
were washed with 1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI 
reagent (Ambion Inc., Austin, TX, USA). Total RNA was extracted according to the 
manufacturer‟s protocol (Sigma, St. Louis, MO). After isolation, the total RNA was 
dissolved in 20 μl diethyl pyrocarbonate (DEPC) water. The RNA concentration was 
determined using Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.   
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of 
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water 
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before 
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with 
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA. 
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The mixed RNA samples was subsequently combined with 2 μl Random  primers 
(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl 
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples 
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse 
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M 
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The 
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop 
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR. 
Quantitative, Real-Time PCR (qPCR) Analysis:  Gene-specific forward and 
reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA) 
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C.  The 
information of the primers and probes are shown in table 4.1. Each set of gene-specific 
primers was tested to determine the maximal concentration of primers that could be used 
to produce specific amplification of the target sequence without primer dimer 
amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3-
phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for 
reverse transcription efficiency and well-to-well variation in template. PCR was 
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City, 
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction 
volume to 20 μl.  QRT-PCR was performed in 364 well plates (Axygen Scientific, Union 
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City, 
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR 
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each 
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cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied 
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in 
separate wells in triplicate. These relative values are plotted against the threshold value 
for each dilution to generate a standard curve. An arbitrary value of template was 
assigned to the highest standard and corresponding values were assigned to the 
subsequent dilutions. According to the slope and y-intercept of the standard curve, 
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each 
experimental and Gapdh triplicate. The value of the average of the experimental triplicate 
divided by the average of the Gapdh triplicate was used for statistical analysis. 
Western Blot Analyses: The protein samples were resolved by SDS-
polyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10% 
separating gel. Protein samples were loaded together with loading buffer and the 
separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA). 
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST 
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20)  for 1 hour with gentle 
shaking in order to block the nonspecific proteins. After that, the blots were probed with 
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The 
membrane was then incubated with primary antibody against phospho-AKT (Cell 
Signaling Technology, Danvers, MA), phospho-ERK1/2 (Cell Signaling Technology), 
phospho-SAPK/JNK (Cell Signaling Technology), or phospho-STAT3 (Cell Signaling 
Technology) overnight at 4°C with gentle shaking. Blots were washed with 1X TBST 
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted 
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% 
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(v/v) Tween 20).  Proteins were incubated with West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific, 
Fairlawn, IL) in dark room.  After the visualization of phosphorylated protein, the blots 
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room 
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked 
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT, 
total ERK1/2, total SAPK/JNK, or total STAT3 (Cell Signaling Technology) overnight at 
4°C with gentle shaking.  Total protein was exposed and visualized as described above.  
The visualized total protein served as a loading control for each sample. The 
autoradiograph images films were scanned and the density of the protein band was 
determined in Photoshop. Semi-quantitative analysis of band density of the 
phosphorylated and total protein was calculated in each film as described by Miller 
(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html). The 
amount of phosphorylated protein was normalized by total protein expressed in each 
sample. The normalized abundance of phosphorylated protein of each sample was 
subsequently compared to the untreated control sample. The data was showed as a fold-
change. 
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism 
4.0 (Graphpad Software, La Jolla, CA). QPCR data and western-blot data were analyzed 
using one-way ANOVA. Differences in data were considered statistically significant at P 
< 0.05. Different letters indicate significant differences in fold change in mRNA 
abundance compared to control for all qPCR data and phospho-protein/total 
protein ratio in time course. The Error bars represent mean ± SE. 
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Results 
Significant gene expression differences In HeLa cells by IL-6 
To determine the effects of IL-6 on the regulation of immediate early genes, HeLa 
cells were treated with 10ng/ml of IL-6 in a time course after 24h serum starvation.  FOS, 
IL-8 and MCP-1 have significant elevated mRNA expression level early in 1 hour, as 
compared to untreated control cells. FOS mRNA increased by 2 fold, IL-8 by 7 fold, and 
MCP-1 by 2 fold, respectively. After these peak increases in mRNA abundance, their 
mRNA expression decreased quickly. Interestingly, IL-6 is able to induce its own mRNA 
with an increase of 2 fold early at 0.5 hour. IL-6 mRNA induction arrived at peak at 1 
hour, and dropped back to control level at 2 hours. However, IL-6 didn't lead to 
significant induction on JUN and caspase 10 (Fig 4.1).  The role of IL-6 on mRNA 
induction of epithelial-mesenchymal transition marker genes was also assessed in the IL-
6 treated HeLa cells.  SNAI1 mRNA was induced to 1.6 times control level. However, 
IL-6 had no significant effect on mRNA level of SNAI2, ZEB2, TWIST1 and JAG1 (Fig 
4.2). 
Signaling Pathways regulated by IL-6 in HeLa cells 
Here, we tested if 10ng/ml of IL-6 changes phosphorylation of ERK1/2 and JNK-
STAT. Fig 4.3 showed that 10ng/ml IL-6 activated ERK1/2 by increasing 
phosphorylation of  ERK1/2 dependent of time. Early in 15 minutes, phosphorylation 
of  ERK1/2 increased by 4 fold in the induction of IL-6. In Fig 4.4, 10ng/ml IL-6 
activated SAPK/JNK by increasing their phosphorylation by 2.5 fold in 15 minutes. But 
phosphorylation of  SAPK/JNK decreased quickly by 30 minutes post-treatment. In 
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contrast, 10ng/ml IL-6 activated STAT3 by increasing its phosphorylation by 6 fold in 15 
minutes and p-STAT-3 began to decrease after 30 minutes. 
Significant gene expression differences In HeLa cells by TNFα 
We also determined the effects of another important inflammation factor, TNFα, 
on the regulation of immediate early genes. HeLa cells were treated with 10ng/ml of 
TNFα in a time course after 24h serum starvation (Fig 4.5).  JUN, FOS and IL-6 had 
significant elevated mRNA expression level 30 minutes after treatment was initiated 
compared to untreated control cells. JUN mRNA increased by 4-fold, FOS by 7-fold, and 
IL-6 by 2-fold.  TNF  (10ng/ml) was also able to increase IL-8, MCP-1 mRNA at 1 
hour. However, 10ng/ml of TNFα didn't lead to significant induction on pro-apoptotic 
factor caspase 10. Fig 4.6 indicated that TNFα was also not able to lead to significant 
induction of SNAI1, SNAI2, ZEB2, or TWIST1 mRNA, whereas JAG1 mRNA 
expression was increased 2 hours post-treatment.  
Signaling Pathways regulated byTNFα in HeLa cells 
Here, we tested if 10ng/ml of TNFα changes phosphorylation of  ERK1/2 and 
JNK-STAT. Fig 4.7 showed that 10ng/mlTNFα activated ERK1/2 by increasing 
phosphorylation of  ERK dependent of time. Early in 15 minutes, phosphorylation 
of ERK1/2 increased by 5.5 fold in the induction of TNFα. However, phosphorylation 
of ERK1/2 got weaker and weaker after that. In Fig 4.7 and Fig 4.8, 10ng/ml TNFα 
activated SAPK/JNK by increasing their phosphorylation by 7 fold in 15 minutes. But 
phosphorylation of SAPK/JNK decreased quickly in another 15 minutes. In contrast, 
10ng/mlTNFα activated STAT3 by increasing its phosphorylation by 1 fold in 15 
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minutes. Interestingly, p-STAT-3 kept increasing. At 1 hour, p-STAT-3 increased by 3.5 
fold. 
 
Discussion 
Inflammation is recognized to play important role in the pathogenesis of many 
types of malignancies. Now, more and more attention has been focused on the role 
cytokine of NF- B, IL-6, TNFα and their signal pathway in mediating the link between 
inflammation and cancer. Michael Karin‟s group reported the elevated levels of IL-6 in 
murine models of colitis-associatedcancer (CAC) (17). The higher serum levels of IL-6 
exhibited in males could be the reason of gender bias in liver cancer susceptibility (18). 
In our data, with the treatment of IL-6 in HeLa cell, there is a increased IL-6 mRNA 
level. It seems as a positive feedback of IL-6 in inflammation. However, IL-6 promotes 
the in vivo growth of tumors in models of prostate, breast, and lung cancers (10). The 
increased IL-6 may be the important link between inflammation and cancer, which 
promotes the tumorigenesis.  
Our data also demonstrated that IL-6 is able to increase FOS mRNA level in 0.5 
hour in HeLa cells. However, the JUN mRNA level was not induced significantly. 
Therefore in our experiments, it is hard to evaluate the induction of AP-1 through IL-6 
treatment. Apparently, as a pro-inflammatory factor, IL-6 is able to induce other 
cytokines' transcription, including IL-8, MCP-1 in our data. IL-8 has been shown to 
contribute to human cancer progression through its potential functions as a mitogenic, 
angiogenic, and motogenic factor. IL-8 expression is regulated by various tumor 
microenvironment factors, such as hypoxia, acidosis, nitric oxide, and cell density (19). 
Le reported that IL-8 plays an important role in tumor angiogenesis and contributes 
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significantly to the aggressive biology of human pancreatic cancer (20).  Moreover, 
point-mutation of NF- B, AP-1, or IL-6 binding sites significantly reduced or eliminated 
the constitutive IL-8 promoter activity (20). As induced expression by IL-6 in HeLa cell, 
the increased IL-8 may stimulate tumorigenesis. MCP-1 is a relevant negative regulator 
of pancreatic cancer progression (21). All primary tumors were tested, and 6 of 14 
pancreatic cancer cell lines were constitutively secreted MCP-1. The increased MCP-1 in 
HeLa cell may be produced by the high activated HeLa cell or induced by pro-
inflammatory cytokine which produced by HeLa cell or the treatment of IL-6.  
IL-6 is an important cytokine, which acts as both a pro-inflammatory and anti-
inflammatory factor. IL-6-type cytokines bind to plasma membrane receptor complexes, 
then induce transducing receptor chain gp 130 (glycoprotein 130), then activate the 
associated Janus kinases (JAKs). STAT3 is a nuclear transcription factor downstream of 
gp130. JAKs phosphorylate gp130, leading to the recruitment and activation of the 
STAT3 and STAT1 transcription factors as well as other molecules (SHP2, Ras-MAPK, 
and PI3K) (22). As Our western-blot data in HeLa cell, IL-6 activate phosphorylation of 
ERK1/2, SAPK/JNK, and STAT3 early at 15 minutes, with continued increased 
phosphorylation of STAT3 at 30min. As reported by Grivennikov and Bollrath, STAT is 
necessary for the growth of colitis-associated colorectal cancer in mice (12, 23). STAT3 
could induce and maintain a procarcinogenic inflammatory microenvironment, both at 
the initiation of malignant transformation and during progression of cancer (12, 24, 25). 
STAT3 is linked to inflammation associated tumorigenesis through genetic alterations in 
malignant cells (26-28).  In fact, STAT3 is frequently activated in malignant cells and 
capable of inducing a large number of genes which are important for inflammation (29). 
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In fact, STAT3 signalling is a major intrinsic pathway for cancer inflammation.  IL-6 and 
Stat3 are required for survival of intestinal epithelial cells and development of colitis-
associated cancer. Take together, ERKs, JNK, STAT3 may be widely expressed protein 
kinase intracellular signalling molecules that are involved in meiosis, mitosis. 
It is reported that an inflammatory stimulus induces production of TNFα, and then 
TNFα could primarily induce production of Il-1, IL-6, IL-8 and other pro-inflammatory 
mediators (30, 31). In our experiment, we also used TNF alpha as the inducer in HeLa 
cells. TNF alpha is able to lead to much stronger induction than did IL-6. In other words, 
TNF alpha is sufficient to activate downstream genes in mRNA level. With TNFα 
treatment, IL-6 had significant elevated mRNA expression level early in 0.5 hour, as 
compared to control, while IL-8, MCP-1 mRNA with increase of 2 fold, 0.6 fold 
respectively at 1 hour.  The treatment of TNFα induces the production of IL-6, IL-8 and 
MCP-1. The increased IL-6 and IL-8 may promote the tumorigensis as discuss above.  
 In addition, TNFα induce the increase of JUN mRNA by 4 fold, FOS by 7 fold in 
HeLa cell. It is established that AP-1 proteins participate in tumorigenesis by regulating 
oncogenic transformation, proliferation, apoptosis, invasive growth and angiogenesis. Fos 
and FosB are dispensable for cell cycle progression, for example, fibroblasts and 
embryonic stem cells have proliferation defect if lacking these components (32-34). 
Moreover, over-expression of c-Fos induces cell death  and resistant to apoptosis in an 
embryonic Syrian hamster cell line (35). Over-expressed c-Fos transforms in 
chondroblasts and osteoblasts, can induced the c-Fos-induced tumorigenesis (36, 37).  In 
fact, dependent on its ability to heterodimerize with Jun proteins and to bind to DNA, c-
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Fos acts as oncogenic. The dramatic induction of JUN and FOS mRNA level caused by 
TNFα in HeLa cells may cause promotion of tumor. 
However, TNFα is commonly used to treat cancer in clinical for it can be pro-
angiogenic and used clinically to destroy tumor vasculature (38). Recently,TNFα is used 
in cancer in the regional treatment of locally advanced soft tissue sarcomas and 
metastatic melanomas and other tumors (16). TNFα is a potent anti-vascular cytokine at 
higher doses. But TNF-α has powerful and toxic systemic side effects at the high dose 
which limited uses in clinical (39). Paradoxically, TNFα is highly expresses in tumor and 
recognized as pro-angiogenic with low dose (39). Although over the last few decades 
high-dose administration of TNF-a has been used as a cytotoxic agent, recent pre-clinical 
cancer models have support that chronic, low level TNF-a exposure cause the  acquisition 
of pro-malignant phenotype including increased growth, invasion and metastasis (40).  
The growth of new capillaries into the tumor is called „tumorangiogenesis‟ (41, 42). 
Angiogenesis is induced by the release of various proangiogenic cytokines by the tumor 
cells and the supporting cells (43).  Pro-angiogenic factors involve in endothelial cell 
proliferation and migration, the formation of endothelial cells into new vasculature, and 
the degradation of the basement membrane and the extracellular matrix (43), which are 
important for the tumor growth.  Low dose of TNFα works as pro-angiogenic factor and 
may promote the tumorigenesis. The 10ng/ml TNFα in HeLa cell induce so many pro-
inflammatory factor which may promote the tumorigenesis and the low dose may also 
work as a pro-angiogenic factor and tumor-promoter to have positive function to tumor 
growth.  
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In the signal pathway,TNFα activated ERK1/2 by increasing phosphorylation 
of  ERK1/2 early at 15 minutes by 5.5 fold in the induction ofTNFα. While the 
phosphorylation SAPK/JNK increase by 7 fold at 15 minutes. However, 10ng/mlTNFα 
activated STAT3 by increasing its phosphorylation from 15 minutes to 1 hour. This 
provides a clue that ERK and JNK-STAT are mediators to deliverTNFα signal to increase 
some downstream target gene expression.  Stat3 can be a link between inflammation and 
cancer. STAT3 could induce and maintain a procarcinogenic inflammatory 
microenvironment, both at the initiation of malignant transformation and during 
progression of cancer (12, 24, 25). STAT3 is linked to inflammation associated 
tumorigenesis through genetic alterations in malignant cells (26-28).  In cancer cell, 
Grivennikov and Bollrath demonstrate that STAT3 is necessary for the growth of colitis-
associated colorectal cancer in mice (12, 23). It may provide another key to 
understandTNFα as a pro-inflammation cytokine and its function in tumorigenesis.  
In normal conditions, cytokines are known to have both tumor-promoting and 
inhibitory effects on breast cancer growth depending presumably on their relative 
concentrations with presence of other modulating factors (10).  In fact, obesity is 
associated with a chronic inflammatory response characterized by over expressed 
cytokine such as IL-6 ,TNFα, adiponectin, inhibitor of NF-kB kinase b (IKKb), 
macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth 
factor, plasminogen activator inhibitor 1 and haptoglobin; increased acute-phase 
reactants, and activation of inflammatory signaling pathways (1, 2). There is an increased 
expression ofTNFα in adipose tissue in human obesity (44). The adipose cell produced 
bioactive peptides  including vascular endothelial growth factor, hepatocyte growth 
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factor, leptin, tumor necrosis factor-alpha, heparin-binding epidermal growth factor-like 
growth factor, and interleukin-6 (11). The inflammatory conditions in obesity may 
initiate or promote oncogenic transformation, and also can generate an inflammatory 
microenvironment that promotes tumour progression. Take together, the effects and 
function of the elevations of the cytokines in obesity may be a link to understand more 
about the obesity related cancer. To understand the important roles of TNF-a and IL-6 in 
the process of tumor promotion will assist in the development of cancer therapeutics.  
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Table 4.1. Human  Primer sequences used for QPCR analysis 
 
Gene Probe  
Dye  
 
Primer Sequence (5' to  3') 
CASP10 SYBR Green  
 
Forward GGAGCTGTCTACTCTTCGGATGA 
Reverse AGGGCTGTGAAGTGAGACATGAT 
FOS SYBR Green  
 
Forward CCTCGCCCGGCTTTG 
Reverse GCCTCGTAGTCTGCGTTGAAG 
JUN SYBR Green  
 
Forward CTGGGAGGACCGGAGACA 
Reverse GAGAAGCCTAAGACGCAGGAAA 
MCP-1 SYBR Green  
 
Forward CAAGCAGAAGTGGGTTCAGGAT 
Reverse TCTTCGGAGTTTGGGTTTGC 
IL-6 SYBR Green  
 
Forward AGGGCTCTTCGGCAAATGTA 
Reverse GAAGGAATGCCCATTAACAACAA 
IL-8 SYBR Green  
 
Forward CTGGCCGTGGCTCTCTTG 
Reverse CCTTGGCAAAACTGCACCTT 
SNAI1 SYBR Green  
 
Forward CCCCAATCGGAAGCCTAACT 
Reverse GCTGGAAGGTAAACTCTGGATTAGA 
SNAI2 SYBR Green  
 
Forward CCTGGGCGCCCTGAA 
Reverse TTCTCCCCCGTGTGAGTTCT 
TWIST1 SYBR Green  
 
Forward TCCGCGTCCCACTAGCA 
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC 
ZEB2 SYBR Green  
 
Forward CCAGCTCGAGCGGCATA 
Reverse GCCACACTCTGTGCATTTGAA 
JAG1 SYBR Green  
 
Forward CAGCTCTGTGACAAAGATCTCAATTAC 
Reverse AGGGCCTGTGTTGCTACAAGTT 
GAPDH Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems  
(VIC Probe) 
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CHAPTER 5 
Summary 
 
In this thesis, we have demonstrated that the abnormal adipocytekines play an important 
role in obesity associated increased cancer risk in obesity. We believe that the data in this thesis 
support our hypothesis that Obesity-associated adipocytokines regulate IE, and EMT genes 
expression profile of HeLa cells and in uterus of LY mouse.  
IGF-1 activates signaling pathways of AKT, Erk1/2, STAT3 and SAPK/JNK and then 
regulates IE and EMT genes. Activated PI3/AKT by IGF-1 can stimulate c-Jun N-terminal 
kinase (JNK) and then stimulates AP-1 transcription. In addition, leptin activates signaling 
pathways of STAT3 and SAPK/JNK and then regulate of IE genes.  However, IL-6 and TNFα 
can both activate signaling pathways of Erk1/2, STAT3 and SAPK/JNK and then regulate of IE 
and EMT genes. The activated pStat3 by IGF-1, or leptin, or IL-6 or TNFα, enhance SIS-induced 
enhancer of AP-1 transcription. Activation of ERK2 can cause the activation of MAPK pathway 
and then increase AP-1 transcription.  In addition, phosphorylation of SAPK/JNK by the 
adipocytokines stimulates AP-1 transcription. AP-1 transcription factors enhance the induced 
EMT by IGF-1, or leptin, or IL-6 or TNFα. In all, the increased IE may increase the cell survival 
and promote tumorigensis. The activation of EMT also protects from cell death and promotes 
tumorigensis. Moreover, the increased pro-inflammatory cytokines including IL-6, IL-8, MCP-1 
may cause inflammatory environment in obesity. The inflammatory environments may initiate or 
promote oncogenic transformation. All the relationships are showed in the figure 6.1. 
Taken together, there is a link between adipocytokine and the expression of genes 
associated with cell proliferation and migration. The adipocytokine plays an important role in the 
initiation and metastasis of tumors in obesity. These changes in gene expression may provide a 
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plausible mechanism for obesity-dependent increases risk in cancers of the female reproductive 
tract.   
 
 
Figure 5.1.  Experimental working model. The relationship between the four 
adipocytokins and obesity associated cancer in my experiments. 
 
 
 
 
 
